| HOME | MEETINGS | MEMBERSHIP | EXHIBITORS | AWARDS | INFO | NEWS | ABOUT US | CONTACT | SIGN IN |
ensuring knowledge, enhancing quality
A 'not-for-profit' organisation,
run for pharmaceutical analysts by pharmaceutical analysts
JPAG - PAST MEETINGS
PAST EVENTS: 1970-2010
RETURN TO MEETINGS
Here are some of our past meetings:
Thursday 26th September 2024
Analytical Strategy to support Continuous Manufacturing
Royal Society of Chemistry, London
Continuous manufacturing offers great promise in improving productivity, efficiency and the intrinsic quality of both active pharmaceutical ingredients and formulated products.
This symposium will critically examine some of the analytical and quality challenges and opportunities that arise from adopting continuous manufacturing, with examples of how to address them. The symposium also presents an introduction to ICH Q13 and its impact on pharmaceutical analysis.
Leading regulators, industrialists and academics will be sharing their experiences in the development, manufacturing and quality assurance of continuous manufacturing of drug substances and drug products.
The meeting is open to the submission of abstracts for oral presentations or posters in line with the above proposed key themes.
Speakers:
Guy Atherton - GSK
Dr Max Besenhard - University College London
Dr Ian Clegg - AstraZeneca
Dr Sean Clifford - AstraZeneca
Phil Doherty - Expo Process Analytics
Uwe Kirschner - Sentronic GmbH
John Mack - Applied Materials
Dr Deborah Mcelhone - Centre for Process Innovation
Dr Patrick Wray - Bristol-Myers Squibb
DETAILS
Analytical Strategy to support Continuous Manufacturing
Royal Society of Chemistry, London
Continuous manufacturing offers great promise in improving productivity, efficiency and the intrinsic quality of both active pharmaceutical ingredients and formulated products.
This symposium will critically examine some of the analytical and quality challenges and opportunities that arise from adopting continuous manufacturing, with examples of how to address them. The symposium also presents an introduction to ICH Q13 and its impact on pharmaceutical analysis.
Leading regulators, industrialists and academics will be sharing their experiences in the development, manufacturing and quality assurance of continuous manufacturing of drug substances and drug products.
The meeting is open to the submission of abstracts for oral presentations or posters in line with the above proposed key themes.
Speakers:
Guy Atherton - GSK
Dr Max Besenhard - University College London
Dr Ian Clegg - AstraZeneca
Dr Sean Clifford - AstraZeneca
Phil Doherty - Expo Process Analytics
Uwe Kirschner - Sentronic GmbH
John Mack - Applied Materials
Dr Deborah Mcelhone - Centre for Process Innovation
Dr Patrick Wray - Bristol-Myers Squibb
DETAILS
Thursday 11th July 2024
Laboratories of the Future
Royal Society of Chemistry, London
The embedding of Industry 4.0 practices within the pharmaceutical industry boosted and accelerated pharmaceutical development: manufacturing, product development and testing have all benefited from the many advancements in the fields of automation, robotics, big data and machine learning. This symposium will feature highlights from industry experts and vendors on trends and case studies showing how industry has adopted (or is considering) new digital and hardware tools to boost efficiency and sustainability in the pharmaceutical laboratories of the future.
Talks will feature a range of topics including:
- Evolution of pharmaceutical processes from industry 1.0 to 4.0
- Virtual reality and artificial intelligence in chemistry laboratories
- Automation of sample preparation
- Predictive modelling of qSAR
- Chemometrics for spectral data analysis
- Chemometrics for metabolomics workflow
- Pharmaceutical forensics
Additionally, we would like to open a call for poster abstracts related to these themes.
Poster submissions are welcome for new or previously presented work and should be submitted by June 20th via events@jpag.org. Abstracts will be reviewed upon submission and authors will be notified by email if their abstract has been accepted or, if revisions are required, feedback will be provided. Authors will be expected to address any feedback / recommendations and conditions of acceptance prior to final submission.
Speakers:
Andy Holwell - ZEISS
Dr Ravi Kalyanaraman - Bristol Myers Squibb
Prof Darrin Baines - Clarivate
Prof Richard Brereton - University of Bristol
Prof Tom Fearn - University College London
Pamela Harrison - AstraZeneca
Dr Stephen Hilton - University College London
Sara Martini - AstraZeneca
Dr Ria Mitchell - Carl Zeiss Microscopy Limited
Dr Lucy Morgan - Pfizer
DETAILS
Laboratories of the Future
Royal Society of Chemistry, London
The embedding of Industry 4.0 practices within the pharmaceutical industry boosted and accelerated pharmaceutical development: manufacturing, product development and testing have all benefited from the many advancements in the fields of automation, robotics, big data and machine learning. This symposium will feature highlights from industry experts and vendors on trends and case studies showing how industry has adopted (or is considering) new digital and hardware tools to boost efficiency and sustainability in the pharmaceutical laboratories of the future.
Talks will feature a range of topics including:
- Evolution of pharmaceutical processes from industry 1.0 to 4.0
- Virtual reality and artificial intelligence in chemistry laboratories
- Automation of sample preparation
- Predictive modelling of qSAR
- Chemometrics for spectral data analysis
- Chemometrics for metabolomics workflow
- Pharmaceutical forensics
Additionally, we would like to open a call for poster abstracts related to these themes.
Poster submissions are welcome for new or previously presented work and should be submitted by June 20th via events@jpag.org. Abstracts will be reviewed upon submission and authors will be notified by email if their abstract has been accepted or, if revisions are required, feedback will be provided. Authors will be expected to address any feedback / recommendations and conditions of acceptance prior to final submission.
Speakers:
Andy Holwell - ZEISS
Dr Ravi Kalyanaraman - Bristol Myers Squibb
Prof Darrin Baines - Clarivate
Prof Richard Brereton - University of Bristol
Prof Tom Fearn - University College London
Pamela Harrison - AstraZeneca
Dr Stephen Hilton - University College London
Sara Martini - AstraZeneca
Dr Ria Mitchell - Carl Zeiss Microscopy Limited
Dr Lucy Morgan - Pfizer
DETAILS
Thursday 16th May 2024
Paediatric Medicines: New and Innovative Development Approaches
Royal Society of Chemistry, London
Development of paediatric formulations is linked to many challenges related to safety, efficacy, acceptability and patient adherence. The latter is a major challenge often dismissed in studies that particularly focus on the safety and efficacy of medicines. In addition, adherence can vary depending on the formulation and route of administration e.g. oral, parenteral, inhalation, etc…
This symposium focuses on integrated approaches across academia and industry to address challenges in the development, safety and efficacy of paediatric formulations and includes the key themes below:
- Safety of paediatric formulations
- Age appropriate formulations
- Challenges in paediatric drug delivery and clinical trials
- Advances in oral paediatric medicines
- Formulation development and characterisation of paediatric formulations
- Analysis in complex matrixes
- Taste assessment of formulation: acceptability versus safety
- Regulatory aspects
Call for posters
We would like to open the call for poster abstracts related to these themes.
Poster submissions are welcome for new or previously presented work and should be submitted by the end of March via events@jpag.org. Abstracts will be reviewed upon submission and authors will be notified by email if their abstract has been accepted or, if revisions are required, feedback will be provided. Authors will be expected to address any feedback / recommendations and conditions of acceptance prior to final submission.
Key dates:
Abstract submission deadline: 15th April 24
Posters will be on display during the day and poster presenters are encouraged to be available for discussion during break times. More information about poster submission can be found here.
Speakers:
Dr Sara Arenas-lopez - Paediatric Critical Care, Evelina London
John Bardsley - Thistle Pharma Limited
Dr Hannah Batchelor - Strathclyde Institute of Pharmacy and Biomedical Sciences
Joanne Botterill - Senior Scientist, AstraZeneca
Elizabeth Galella - Bristol Myers Squibb
Sian Gaze - Medicine and Neonatology, Evelina London
Dr Dan Hawcutt - Alder Hey Childrens Hospital
Dr Alice McCloskey - Liverpool John Moores University
Dr Shiva Ramroop - Team lead for Paediatric Unit HQA, MHRA
Dr Catherine Tuleu - University College London
DETAILS
Paediatric Medicines: New and Innovative Development Approaches
Royal Society of Chemistry, London
Development of paediatric formulations is linked to many challenges related to safety, efficacy, acceptability and patient adherence. The latter is a major challenge often dismissed in studies that particularly focus on the safety and efficacy of medicines. In addition, adherence can vary depending on the formulation and route of administration e.g. oral, parenteral, inhalation, etc…
This symposium focuses on integrated approaches across academia and industry to address challenges in the development, safety and efficacy of paediatric formulations and includes the key themes below:
- Safety of paediatric formulations
- Age appropriate formulations
- Challenges in paediatric drug delivery and clinical trials
- Advances in oral paediatric medicines
- Formulation development and characterisation of paediatric formulations
- Analysis in complex matrixes
- Taste assessment of formulation: acceptability versus safety
- Regulatory aspects
Call for posters
We would like to open the call for poster abstracts related to these themes.
Poster submissions are welcome for new or previously presented work and should be submitted by the end of March via events@jpag.org. Abstracts will be reviewed upon submission and authors will be notified by email if their abstract has been accepted or, if revisions are required, feedback will be provided. Authors will be expected to address any feedback / recommendations and conditions of acceptance prior to final submission.
Key dates:
Abstract submission deadline: 15th April 24
Posters will be on display during the day and poster presenters are encouraged to be available for discussion during break times. More information about poster submission can be found here.
Speakers:
Dr Sara Arenas-lopez - Paediatric Critical Care, Evelina London
John Bardsley - Thistle Pharma Limited
Dr Hannah Batchelor - Strathclyde Institute of Pharmacy and Biomedical Sciences
Joanne Botterill - Senior Scientist, AstraZeneca
Elizabeth Galella - Bristol Myers Squibb
Sian Gaze - Medicine and Neonatology, Evelina London
Dr Dan Hawcutt - Alder Hey Childrens Hospital
Dr Alice McCloskey - Liverpool John Moores University
Dr Shiva Ramroop - Team lead for Paediatric Unit HQA, MHRA
Dr Catherine Tuleu - University College London
DETAILS
Thursday 21st March 2024
Considering the raw materials: API & Excipients
Royal Society of Chemistry, London
Raw materials, APIs and excipients play an important role in the manufacturing of pharmaceutical products therefore it is important to assess and monitor quality of these materials throughout the product lifecycle. This symposium will present an overview of testing and risk assessment of these pharmaceutical product components throughout the life cycle with presentations and a panel discussion covering topics related to our key themes below:
- pharmacopoeial monographs for assessing raw materials
- regulatory perspectives (ICH Q7, ICH Q11) covering aspects for small molecules, biologics and ATMPs
- risk assessment of raw materials
- Good Manufacturing Practice
- physical testing including incoming receipt of API & excipients
- method optimisation and development
- stability of APIs
- supply chain impact & resilience
- sustainability
The meeting is open to the submission of "poster abstracts for Mar-24" and "questions for the Mar-24 panel" in line with the above proposed key themes, as per our guidance on the information page.
Speakers:
Dr Ralph Adams - Manchester University & RSC NMR group
Dr Hisham Al-Obaidi - University of Reading School of Pharmacy
Rodrigo Arias - DFE Pharma & IPEC Federation
Iain Moore - EXCiPACT asbl
Richard Smalley - Consultant and QP Assessor
Trevor Watson - MHRA
Michael Whaley - Medicines and Healthcare products Regulatory Agency (MHRA)
Antonia Wierzbicki - Waters
DETAILS
Considering the raw materials: API & Excipients
Royal Society of Chemistry, London
Raw materials, APIs and excipients play an important role in the manufacturing of pharmaceutical products therefore it is important to assess and monitor quality of these materials throughout the product lifecycle. This symposium will present an overview of testing and risk assessment of these pharmaceutical product components throughout the life cycle with presentations and a panel discussion covering topics related to our key themes below:
- pharmacopoeial monographs for assessing raw materials
- regulatory perspectives (ICH Q7, ICH Q11) covering aspects for small molecules, biologics and ATMPs
- risk assessment of raw materials
- Good Manufacturing Practice
- physical testing including incoming receipt of API & excipients
- method optimisation and development
- stability of APIs
- supply chain impact & resilience
- sustainability
The meeting is open to the submission of "poster abstracts for Mar-24" and "questions for the Mar-24 panel" in line with the above proposed key themes, as per our guidance on the information page.
Speakers:
Dr Ralph Adams - Manchester University & RSC NMR group
Dr Hisham Al-Obaidi - University of Reading School of Pharmacy
Rodrigo Arias - DFE Pharma & IPEC Federation
Iain Moore - EXCiPACT asbl
Richard Smalley - Consultant and QP Assessor
Trevor Watson - MHRA
Michael Whaley - Medicines and Healthcare products Regulatory Agency (MHRA)
Antonia Wierzbicki - Waters
DETAILS
Thursday 25th January 2024
Oligonucleotides - Stuck in the middle with you
Royal Society of Chemistry, London
They aren’t quite big, but they’re certainly not small. As such oligonucleotides present a unique challenge to pharmaceutical scientists and engineers; as well as a massive opportunity.
JPAG and the APS Materials Science focus group will be working together to deliver a joint seminar which will address the discovery and manufacturing challenges of oligonucleotide processing, from the joint perspectives of small and large molecule analytics and materials science.
Split across two sessions (morning and afternoon) we will look at the unique challenges and massive opportunity of oligos through the lenses of small and large molecule approaches.
Speakers:
Samuel Whitmarsh - CatSci
Thomas Bridge - Intellegens
Dr Ken Cook - Thermo Fisher Scientific
Claire Macleod - CPI
Dr Nigel Richardson - CatSci
Prof Geoff Smith - De Montfort University
Maire Welham - AstraZeneca
DETAILS
Oligonucleotides - Stuck in the middle with you
Royal Society of Chemistry, London
They aren’t quite big, but they’re certainly not small. As such oligonucleotides present a unique challenge to pharmaceutical scientists and engineers; as well as a massive opportunity.
JPAG and the APS Materials Science focus group will be working together to deliver a joint seminar which will address the discovery and manufacturing challenges of oligonucleotide processing, from the joint perspectives of small and large molecule analytics and materials science.
Split across two sessions (morning and afternoon) we will look at the unique challenges and massive opportunity of oligos through the lenses of small and large molecule approaches.
Speakers:
Samuel Whitmarsh - CatSci
Thomas Bridge - Intellegens
Dr Ken Cook - Thermo Fisher Scientific
Claire Macleod - CPI
Dr Nigel Richardson - CatSci
Prof Geoff Smith - De Montfort University
Maire Welham - AstraZeneca
DETAILS
Thursday 7th December 2023
Regulatory Hot Topics VIII
Royal Society of Chemistry, London
This symposium will address an introduction to the issues and challenges associated with use of biowaivers. Additional topics will cover UK and international Recognition & Reliance regulatory procedures as well as updated, new and emerging ICH guidance from 2023 and a look forward into 2024.
The meeting provides an excellent opportunity for dialogue, discussion and debate in an open forum and allows learning from expert speakers involved in the development of guidance and best practice.
The event will be in-person only, at RSC, London.
Speakers:
Rabiea Abdullah - Consultant
Dr Leonard Both - MHRA
Neil Clayton - Pfizer
Peter Crowley - MHRA
Dr Helena Engman - AstraZeneca
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Dr Adele Patterson - Bristol-Myers Squibb
Dr Melanie Pires - Senior Consultant, NDA Group
Priti Shah - AstraZeneca
DETAILS
Regulatory Hot Topics VIII
Royal Society of Chemistry, London
This symposium will address an introduction to the issues and challenges associated with use of biowaivers. Additional topics will cover UK and international Recognition & Reliance regulatory procedures as well as updated, new and emerging ICH guidance from 2023 and a look forward into 2024.
The meeting provides an excellent opportunity for dialogue, discussion and debate in an open forum and allows learning from expert speakers involved in the development of guidance and best practice.
The event will be in-person only, at RSC, London.
Speakers:
Rabiea Abdullah - Consultant
Dr Leonard Both - MHRA
Neil Clayton - Pfizer
Peter Crowley - MHRA
Dr Helena Engman - AstraZeneca
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Dr Adele Patterson - Bristol-Myers Squibb
Dr Melanie Pires - Senior Consultant, NDA Group
Priti Shah - AstraZeneca
DETAILS
Tuesday 21st November 2023
JPAG Pharmaceutical Analysis Research Awards and Careers Symposium 2023
Royal Society of Chemistry, London
Based on the great success of past years, JPAG presents this year's Pharmaceutical Analysis Research Awards and Careers symposium for all early career analytical scientists.
Keynote speakers from industry and academia will provide an inspirational and enlightening talk for delegates - their details will follow shortly. Alongside this, the Careers Fair allows delegates to book one-to-one sessions with advisors from several pharmaceutical companies who can discuss employment options and opportunities with you.
The main symposium programme will additionally provide the opportunity for you to listen to the latest research being carried out by your peers with selected researchers showcasing their work through either oral or poster presentations with opportunities for you to ask questions about their work. We highly encourage all early career scientists across industry and academia (post-graduate students) to submit an abstract for poster or oral presentation to this exciting annual JPAG event and be in with a chance of winning one of the prizes including the prestigious Geoffrey Phillips Analytical Science Award for best oral presentation.
Come along and network with peers, experienced academics, industrial scientists, high profile keynote presenters, and leading companies who are providing careers advice.
Speakers:
Prof John Langley - University of Southampton
Dr Diane Turner - Royal Society of Chemistry
Laura Woodward - Royal Society of Chemistry
DETAILS
JPAG Pharmaceutical Analysis Research Awards and Careers Symposium 2023
Royal Society of Chemistry, London
Based on the great success of past years, JPAG presents this year's Pharmaceutical Analysis Research Awards and Careers symposium for all early career analytical scientists.
Keynote speakers from industry and academia will provide an inspirational and enlightening talk for delegates - their details will follow shortly. Alongside this, the Careers Fair allows delegates to book one-to-one sessions with advisors from several pharmaceutical companies who can discuss employment options and opportunities with you.
The main symposium programme will additionally provide the opportunity for you to listen to the latest research being carried out by your peers with selected researchers showcasing their work through either oral or poster presentations with opportunities for you to ask questions about their work. We highly encourage all early career scientists across industry and academia (post-graduate students) to submit an abstract for poster or oral presentation to this exciting annual JPAG event and be in with a chance of winning one of the prizes including the prestigious Geoffrey Phillips Analytical Science Award for best oral presentation.
Come along and network with peers, experienced academics, industrial scientists, high profile keynote presenters, and leading companies who are providing careers advice.
Speakers:
Prof John Langley - University of Southampton
Dr Diane Turner - Royal Society of Chemistry
Laura Woodward - Royal Society of Chemistry
DETAILS
Thursday 5th October 2023
The Chromatographic (Analytical) method life cycle 2023: From cradle to grave II
Royal Society of Chemistry, London
JPAG and ChromSoc are pleased to announce another meeting in the series: “From cradle to grave: The Chromatographic (Analytical) method life cycle” intending to cover all stages from development, through validation and transfer to continuous performance monitoring. Focussing on analytical life cycle management within the pharmaceutical industry, latest regulatory expectations and permitted chromatographic method changes according to pharmacopoeias, knowledge sharing presentations will be delivered by industry and agency speakers as well as vendor exhibits and case studies with space for poster presenters to share their work in this area.
Speakers:
Brooks Ligon - AstraZeneca
Alexander Blanazs - AstraZeneca
Dr Philip Borman - GlaxoSmithKline
Wayne Callar - Pfizer
Dr Tony Edge - Avantor Sciences
Dr Luis Flores Ortiz - Novartis
Dr Chris Gripton - GSK Medicines Research Centre
Dr Abi Herbert - AstraZeneca
Frank Judge - Butterworth Laboratories
Dr Katrin Liebelt - Novartis
Nathanael Page - Resolian
James Turner - Phenomenex
DETAILS
The Chromatographic (Analytical) method life cycle 2023: From cradle to grave II
Royal Society of Chemistry, London
JPAG and ChromSoc are pleased to announce another meeting in the series: “From cradle to grave: The Chromatographic (Analytical) method life cycle” intending to cover all stages from development, through validation and transfer to continuous performance monitoring. Focussing on analytical life cycle management within the pharmaceutical industry, latest regulatory expectations and permitted chromatographic method changes according to pharmacopoeias, knowledge sharing presentations will be delivered by industry and agency speakers as well as vendor exhibits and case studies with space for poster presenters to share their work in this area.
Speakers:
Brooks Ligon - AstraZeneca
Alexander Blanazs - AstraZeneca
Dr Philip Borman - GlaxoSmithKline
Wayne Callar - Pfizer
Dr Tony Edge - Avantor Sciences
Dr Luis Flores Ortiz - Novartis
Dr Chris Gripton - GSK Medicines Research Centre
Dr Abi Herbert - AstraZeneca
Frank Judge - Butterworth Laboratories
Dr Katrin Liebelt - Novartis
Nathanael Page - Resolian
James Turner - Phenomenex
DETAILS
Monday 3rd July 2023
Impurities in Food and Pharmaceuticals: Can Risk Assessment and Regulation be Aligned?
Royal Society of Chemistry, London
The health risk assessment of impurities is a key part of assuring the safety of food and drugs. Despite the scientific theory of hazard and risk assessment being shared by the two sectors, there are several significant regulatory differences.
This event will look in detail at two case studies - titanium dioxide, which is under scrutiny in the food sector but is widely used in pharmaceuticals, and nitrosamines, which are naturally formed in certain foods but are extremely tightly controlled in medicines. We will discuss the reasons behind the differences, and in a panel session will explore whether there are possibilities for greater alignment between the sectors.
DETAILS
Impurities in Food and Pharmaceuticals: Can Risk Assessment and Regulation be Aligned?
Royal Society of Chemistry, London
The health risk assessment of impurities is a key part of assuring the safety of food and drugs. Despite the scientific theory of hazard and risk assessment being shared by the two sectors, there are several significant regulatory differences.
This event will look in detail at two case studies - titanium dioxide, which is under scrutiny in the food sector but is widely used in pharmaceuticals, and nitrosamines, which are naturally formed in certain foods but are extremely tightly controlled in medicines. We will discuss the reasons behind the differences, and in a panel session will explore whether there are possibilities for greater alignment between the sectors.
DETAILS
Thursday 15th June 2023
Stability VII
Royal Society of Chemistry, London
Continuing our successful series of stability meetings, this 7th event is essential for anyone concerned with the management and assessment of drug stability including respiratory products and unlicensed medicines. We have a group of expert speakers from academia, industry and with a regulatory perspective who will provide background information and new approaches to stability testing.
Hear about particular stability challenges in testing and shelf-life setting for these types of products and learn from our expert speakers on frameworks and practical challenges.
Posters are invited from industry and academia on stability topics to facilitate additional interaction between attendees and speakers.
Speakers:
Prof Parastou Donyai - King's College London
Megan Doran - Intertek
Dr Kate Hadavizadeh - NHS
Joseph Hanna - AstraZeneca
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Dr Paul Marshall - Jazz Pharmaceuticals
Prof Tony Moffat - University College London
Dr Garry Scrivens - Pfizer
DETAILS
Stability VII
Royal Society of Chemistry, London
Continuing our successful series of stability meetings, this 7th event is essential for anyone concerned with the management and assessment of drug stability including respiratory products and unlicensed medicines. We have a group of expert speakers from academia, industry and with a regulatory perspective who will provide background information and new approaches to stability testing.
Hear about particular stability challenges in testing and shelf-life setting for these types of products and learn from our expert speakers on frameworks and practical challenges.
Posters are invited from industry and academia on stability topics to facilitate additional interaction between attendees and speakers.
Speakers:
Prof Parastou Donyai - King's College London
Megan Doran - Intertek
Dr Kate Hadavizadeh - NHS
Joseph Hanna - AstraZeneca
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Dr Paul Marshall - Jazz Pharmaceuticals
Prof Tony Moffat - University College London
Dr Garry Scrivens - Pfizer
DETAILS
Thursday 11th May 2023
The future of spectroscopy: new capabilities and new applications
Royal Society of Chemistry, London
The 21st century have been witnessing an industrial revolution (industry 4.0) where digitisation, data-driven/AI-assisted automation and novel applications have emerged. Spectroscopic techniques offer simplicity, speed and specificity in characterising a wide variety of substances within pharmaceutical and other industries and has been playing an important part in this revolution.
In this special one-day symposium jointly organised by the Molecular Spectroscopy Group and Joint Pharmaceutical Analysis Group, we will discuss the newly emerged/emerging capabilities and applications of novel spectroscopic techniques in the pharmaceutical industry.
We would like to thank Metrohm for their sponsorship of this event
Speakers:
Dr Kofi Asare-Addo - University of Huddersfield
Dr Sulaf Assi - Liverpool John Moores University
Dr K. L. Andrew Chan - King's College London
Prof Richard Guy - University of Bath
Dr Bethan McAvan - AstraZeneca
Prof Alison Nordon - University of Strathclyde
Dr Tran Pham - GlaxoSmithKline
Dr Patrick Wray - Bristol-Myers Squibb
DETAILS
The future of spectroscopy: new capabilities and new applications
Royal Society of Chemistry, London
The 21st century have been witnessing an industrial revolution (industry 4.0) where digitisation, data-driven/AI-assisted automation and novel applications have emerged. Spectroscopic techniques offer simplicity, speed and specificity in characterising a wide variety of substances within pharmaceutical and other industries and has been playing an important part in this revolution.
In this special one-day symposium jointly organised by the Molecular Spectroscopy Group and Joint Pharmaceutical Analysis Group, we will discuss the newly emerged/emerging capabilities and applications of novel spectroscopic techniques in the pharmaceutical industry.
We would like to thank Metrohm for their sponsorship of this event
Speakers:
Dr Kofi Asare-Addo - University of Huddersfield
Dr Sulaf Assi - Liverpool John Moores University
Dr K. L. Andrew Chan - King's College London
Prof Richard Guy - University of Bath
Dr Bethan McAvan - AstraZeneca
Prof Alison Nordon - University of Strathclyde
Dr Tran Pham - GlaxoSmithKline
Dr Patrick Wray - Bristol-Myers Squibb
DETAILS
Thursday 23rd March 2023
Companion diagnostics for precision medicine
Royal Society of Chemistry, London
This one-day symposium will address the development and need for companion diagnostics (CDx) for precision medicine applications. Companion diagnostics are becoming more and more important with time together with the growth of targeted therapies. Precision medicine approach aims to stratify patients with the ultimate aim of targeting patients who are most likely to respond to a specific treatment. Currently, CDx are used for many diseases lung cancer, colorectal cancer, breast cancer and melanoma.
At this symposium, delegates will be able to explore the current state of the art in vitro diagnostic tests used by the industry and explore the different scientific measurements that are needed to develop and deliver a CDx into the market.
CDx is a platform technology and can be used for many other diseases, join us and lets discuss the future of healthcare and personalised treatment.
Online attendance option is available in this meeting via MS Teams.
If you have a NHS/MHRA/academia e-mail address, you may be eligible for a £50 discount for this meeting. Please contact events@jpag.org for further details.
Speakers:
Prof George Hanna - Imperial College London
Graham Fews - West Midlands Regional Genetics Lab / NHS
Prof Lorna Harries - University of Exeter / SENISCA
Dr Stephen Little - Yourgene Health
Dr Dahlia Salman - Bioxhale ltd
Dr Paul Wilson - Intelligent Fingerprinting
Dr Elizabeth Young - NHS
Prof Philip Young - University of Warwick
DETAILS
Companion diagnostics for precision medicine
Royal Society of Chemistry, London
This one-day symposium will address the development and need for companion diagnostics (CDx) for precision medicine applications. Companion diagnostics are becoming more and more important with time together with the growth of targeted therapies. Precision medicine approach aims to stratify patients with the ultimate aim of targeting patients who are most likely to respond to a specific treatment. Currently, CDx are used for many diseases lung cancer, colorectal cancer, breast cancer and melanoma.
At this symposium, delegates will be able to explore the current state of the art in vitro diagnostic tests used by the industry and explore the different scientific measurements that are needed to develop and deliver a CDx into the market.
CDx is a platform technology and can be used for many other diseases, join us and lets discuss the future of healthcare and personalised treatment.
Online attendance option is available in this meeting via MS Teams.
If you have a NHS/MHRA/academia e-mail address, you may be eligible for a £50 discount for this meeting. Please contact events@jpag.org for further details.
Speakers:
Prof George Hanna - Imperial College London
Graham Fews - West Midlands Regional Genetics Lab / NHS
Prof Lorna Harries - University of Exeter / SENISCA
Dr Stephen Little - Yourgene Health
Dr Dahlia Salman - Bioxhale ltd
Dr Paul Wilson - Intelligent Fingerprinting
Dr Elizabeth Young - NHS
Prof Philip Young - University of Warwick
DETAILS
Thursday 8th December 2022
Regulatory Hot Topics VII
Royal Society of Chemistry, London
This symposium will address issues and challenges associated with the implementation of updated, new and emerging guidelines. It will provide and excellent opportunity for dialogue, discussion and debate with speakers and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on various key topics.
An excellent opportunity to learn from expert speakers involved in the development of the guidance and best practice in these challenging subject areas.
This event will be in-person only, at RSC, London.
Speakers:
Dr Karin Boon - MHRA
Helen Corns - MHRA
Stuart Finnie - AstraZeneca
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Laura Jones - AstraZeneca
Sze Mun Tan - MHRA
DETAILS
Regulatory Hot Topics VII
Royal Society of Chemistry, London
This symposium will address issues and challenges associated with the implementation of updated, new and emerging guidelines. It will provide and excellent opportunity for dialogue, discussion and debate with speakers and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on various key topics.
An excellent opportunity to learn from expert speakers involved in the development of the guidance and best practice in these challenging subject areas.
This event will be in-person only, at RSC, London.
Speakers:
Dr Karin Boon - MHRA
Helen Corns - MHRA
Stuart Finnie - AstraZeneca
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Laura Jones - AstraZeneca
Sze Mun Tan - MHRA
DETAILS
Tuesday 22nd November 2022
JPAG Pharmaceutical Analysis Research Awards and Careers Fair 2022
Royal Society of Chemistry, London
Based on the great success of the past years, JPAG presents this year's Pharmaceutical Analysis symposium for postgraduate, undergraduate and early career scientists.
This event will provide the opportunity for you to listen to and hear the latest research being carried out by your peers. Selected researchers will showcase their work through oral and poster presentations, and you will have the opportunity to ask them questions about their work.
The Careers Fair will also feature and allow all delegates to book one-to-one sessions with seven major pharmaceutical companies who are bringing their careers advisors to discuss opportunities with you. This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
Also, we have two very high profile Keynote speakers, who will each provide an inspirational and enlightening talk for delegates. Their details are shown below.
And additionally, the Royal Society of Chemistry's Careers Specialist will conduct a 'CV Surgery' for RSC members; these are one-to-one discussions for members to find out how to present a good CV. So be sure to bring your CV along!
Come along and network with peers, experienced academics, industrial scientists, high profile keynote presenters, and leading companies who are providing careers advice.
This is an event you will not want to miss.
Registration will open at 9am for a 9:30am start, and the day will end with a Careers and Networking wine reception starting at 16:50h.
Keynote speaker: Dr Tony Bristow, AstraZeneca
Tony Bristow is Principal Scientist for Measurement Science at AstraZeneca (Macclesfield, UK) and the technology and capability lead for the Analytical Sciences Leadership Team, within AstraZeneca's Pharmaceutical Technology & Development organisation. These roles are focussed on the development and delivery of analytical science strategy (2018-to date). Prior to this, Tony’s focus was the application and development of mass spectrometry (2005-2018).
Tony is the Chair of the Industry Advisory Board of the Community for Analytical Measurement Science (UK) and a Visiting Professor at the University of Warwick. In addition, Tony is a former member of the Royal Society of Chemistry Analytical Division Council (2013-2019) and former Chair of the British Mass Spectrometry Society (2012-2014).
Tony was awarded a degree in Applied Chemistry in 1992 and his PhD (mass spectrometry) in 1996. Tony previously worked for Kodak and LGC focussed on a variety of analytical science based projects. Tony is an author/co-author of over 40 peer reviewed publications and regularly presents at national and international conferences.
Keynote speaker: Prof Paul Thomas, Bioxhale
Prof Paul Thomas. Led research in ultra-trace volatiles in complex-systems since 1985, and is an international authority in breath, saliva, and skin volatilomic analysis for diagnostics and emergency-care applications. He has raised substantial funds for, and directed, large international consortia, serves on the boards of international research organisations, and has acted as science advisor to UK Gov Cabinet office and MHRA. Responsible for analytical quality-by-design, breath-sampling systems innovation/development, validation of enhanced features and analytical operational concepts.
Title for the talk: Its faster when you fly: an agenda for next-generation measurement systems
Speakers:
Dr Tony Bristow - AstraZeneca
Prof Paul Thomas - Bioxhale
DETAILS
JPAG Pharmaceutical Analysis Research Awards and Careers Fair 2022
Royal Society of Chemistry, London
Based on the great success of the past years, JPAG presents this year's Pharmaceutical Analysis symposium for postgraduate, undergraduate and early career scientists.
This event will provide the opportunity for you to listen to and hear the latest research being carried out by your peers. Selected researchers will showcase their work through oral and poster presentations, and you will have the opportunity to ask them questions about their work.
The Careers Fair will also feature and allow all delegates to book one-to-one sessions with seven major pharmaceutical companies who are bringing their careers advisors to discuss opportunities with you. This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
Also, we have two very high profile Keynote speakers, who will each provide an inspirational and enlightening talk for delegates. Their details are shown below.
And additionally, the Royal Society of Chemistry's Careers Specialist will conduct a 'CV Surgery' for RSC members; these are one-to-one discussions for members to find out how to present a good CV. So be sure to bring your CV along!
Come along and network with peers, experienced academics, industrial scientists, high profile keynote presenters, and leading companies who are providing careers advice.
This is an event you will not want to miss.
Registration will open at 9am for a 9:30am start, and the day will end with a Careers and Networking wine reception starting at 16:50h.
Keynote speaker: Dr Tony Bristow, AstraZeneca
Tony Bristow is Principal Scientist for Measurement Science at AstraZeneca (Macclesfield, UK) and the technology and capability lead for the Analytical Sciences Leadership Team, within AstraZeneca's Pharmaceutical Technology & Development organisation. These roles are focussed on the development and delivery of analytical science strategy (2018-to date). Prior to this, Tony’s focus was the application and development of mass spectrometry (2005-2018).
Tony is the Chair of the Industry Advisory Board of the Community for Analytical Measurement Science (UK) and a Visiting Professor at the University of Warwick. In addition, Tony is a former member of the Royal Society of Chemistry Analytical Division Council (2013-2019) and former Chair of the British Mass Spectrometry Society (2012-2014).
Tony was awarded a degree in Applied Chemistry in 1992 and his PhD (mass spectrometry) in 1996. Tony previously worked for Kodak and LGC focussed on a variety of analytical science based projects. Tony is an author/co-author of over 40 peer reviewed publications and regularly presents at national and international conferences.
Keynote speaker: Prof Paul Thomas, Bioxhale
Prof Paul Thomas. Led research in ultra-trace volatiles in complex-systems since 1985, and is an international authority in breath, saliva, and skin volatilomic analysis for diagnostics and emergency-care applications. He has raised substantial funds for, and directed, large international consortia, serves on the boards of international research organisations, and has acted as science advisor to UK Gov Cabinet office and MHRA. Responsible for analytical quality-by-design, breath-sampling systems innovation/development, validation of enhanced features and analytical operational concepts.
Title for the talk: Its faster when you fly: an agenda for next-generation measurement systems
Speakers:
Dr Tony Bristow - AstraZeneca
Prof Paul Thomas - Bioxhale
DETAILS
Thursday 6th October 2022
Chromatography Techniques: Challenges in Application
VIRTUAL EVENT
Chromatography is an essential technique used in analysis across the pharmaceutical industry. Join us at this event to learn and discuss the challenges associated with application of these techniques for pharmaceutical analysis with experts from industry who will provide background information and case studies to highlight how they have dealt with obstacles and practical issues faced in chromatography analysis and development
Speakers:
Jon Hall - GlaxoSmithKline
Brian He - Bristol-Myers Squibb
Matthew Osborne - AstraZeneca
Dr Emma Simmonds - GlaxoSmithKline
Alec Simpson - GlaxoSmithKline
Dr Peter Tattersall - Bristol Myers Squibb
DETAILS
Chromatography Techniques: Challenges in Application
VIRTUAL EVENT
Chromatography is an essential technique used in analysis across the pharmaceutical industry. Join us at this event to learn and discuss the challenges associated with application of these techniques for pharmaceutical analysis with experts from industry who will provide background information and case studies to highlight how they have dealt with obstacles and practical issues faced in chromatography analysis and development
Speakers:
Jon Hall - GlaxoSmithKline
Brian He - Bristol-Myers Squibb
Matthew Osborne - AstraZeneca
Dr Emma Simmonds - GlaxoSmithKline
Alec Simpson - GlaxoSmithKline
Dr Peter Tattersall - Bristol Myers Squibb
DETAILS
Thursday 30th June 2022
Stability VI
Royal Society of Chemistry, London
Continuing our successful series of stability meetings, this event is essential for anyone concerned with the management and assessment of drug stability. We have a group of expert speakers from academia, the regulator and industry who will provide background information, case studies and innovative approaches to stability testing. Posters are invited from industry and academia on any stability topics to facilitate additional interaction between attendees and speakers. The afternoon session will be split into smaller workshops on "hot" stability topics to allow active dialogue between delegates which will be summarised and closed out by a panel discussion.
Speakers:
Miles Ambler - GlaxoSmithKline
Dr Touraj Ehtezazi - Liverpool John Moores University
Dr Lisa Hinchliffe - Regulatory CMC Consultant
John McDermott - Quotient Sciences
Oona McPolin - Mourne Training Services
Laima Ozolina - Biopharma Stability Testing Laboratory
Dr Alan Wilkinson - Biopharma Stability Testing Laboratory
DETAILS
Stability VI
Royal Society of Chemistry, London
Continuing our successful series of stability meetings, this event is essential for anyone concerned with the management and assessment of drug stability. We have a group of expert speakers from academia, the regulator and industry who will provide background information, case studies and innovative approaches to stability testing. Posters are invited from industry and academia on any stability topics to facilitate additional interaction between attendees and speakers. The afternoon session will be split into smaller workshops on "hot" stability topics to allow active dialogue between delegates which will be summarised and closed out by a panel discussion.
Speakers:
Miles Ambler - GlaxoSmithKline
Dr Touraj Ehtezazi - Liverpool John Moores University
Dr Lisa Hinchliffe - Regulatory CMC Consultant
John McDermott - Quotient Sciences
Oona McPolin - Mourne Training Services
Laima Ozolina - Biopharma Stability Testing Laboratory
Dr Alan Wilkinson - Biopharma Stability Testing Laboratory
DETAILS
Thursday 12th May 2022
Antibody Drug Conjugates Revisited
VIRTUAL EVENT: 1pm-3:40pm UK BST
Antibody drug conjugates (ADCs) are an exciting and challenging new area of research and are becoming ever more popular across the industry with more than 100 ADCs reported in the clinic. The targeted nature of the molecules makes them extremely suitable for delivering toxic molecules to the biological target.
However the complexity of the molecules and the lack of regulatory experience increases the complexity in discovery and development across all disciplines.
This symposium brings together experts from across the industry to share their knowledge and learning for an engaging and exciting meeting.
Members of the RSB can register at the the JPAG Member rate. Just add your RSB membership number.
Speakers:
Dr Penelope Drake - Catalent Biologics
Dr Stuart Dunn - Labcorp
Dr Richard Easton - BioPharmaSpec
Dr Colin McKee - Sterling Pharma
Dr Christiane Niederlaender - Parexel
Prof Miraz Rahman - King's College London
DETAILS
Antibody Drug Conjugates Revisited
VIRTUAL EVENT: 1pm-3:40pm UK BST
Antibody drug conjugates (ADCs) are an exciting and challenging new area of research and are becoming ever more popular across the industry with more than 100 ADCs reported in the clinic. The targeted nature of the molecules makes them extremely suitable for delivering toxic molecules to the biological target.
However the complexity of the molecules and the lack of regulatory experience increases the complexity in discovery and development across all disciplines.
This symposium brings together experts from across the industry to share their knowledge and learning for an engaging and exciting meeting.
Members of the RSB can register at the the JPAG Member rate. Just add your RSB membership number.
Speakers:
Dr Penelope Drake - Catalent Biologics
Dr Stuart Dunn - Labcorp
Dr Richard Easton - BioPharmaSpec
Dr Colin McKee - Sterling Pharma
Dr Christiane Niederlaender - Parexel
Prof Miraz Rahman - King's College London
DETAILS
Thursday 7th April 2022
Automation of sample preparation
VIRTUAL EVENT: 1pm-5pm UK BST
In recent years, most of the innovation seen in the pharmaceutical analysis arena has been on the instrumentation used for measurement and the analysis and interpretation of the data generated. At the same time the molecules coming out of discovery chemistry (often with poor solubility and / or bioavailability), are requiring formulators to develop sample matrices that are becoming increasingly complicated - including but not limited to amorphous solid dispersions, holt-melt extrudates and extended-release formulations. Extraction from these types of samples can be extremely challenging in terms of efficiency, reproducibility, cost, and transferability.
This JPAG symposium will discuss some of the challenges in the topic of sample preparation and provide examples of potential solutions in the form of innovative instrumentation, automation, and the application of existing methodology to inform and educate the audience about advances in sample preparation.
Speakers:
Dr Giorgio Blom - AstraZeneca
Dr Michelle Case - Bristol Myers Squibb
Dr Paola Ferrini - GlaxoSmithKline
Dr Joanne Laukart - Mettler Toledo
Dr Antonio Moreno-Herrera - AstraZeneca
Dr Adele Patterson - Bristol-Myers Squibb
DETAILS
Automation of sample preparation
VIRTUAL EVENT: 1pm-5pm UK BST
In recent years, most of the innovation seen in the pharmaceutical analysis arena has been on the instrumentation used for measurement and the analysis and interpretation of the data generated. At the same time the molecules coming out of discovery chemistry (often with poor solubility and / or bioavailability), are requiring formulators to develop sample matrices that are becoming increasingly complicated - including but not limited to amorphous solid dispersions, holt-melt extrudates and extended-release formulations. Extraction from these types of samples can be extremely challenging in terms of efficiency, reproducibility, cost, and transferability.
This JPAG symposium will discuss some of the challenges in the topic of sample preparation and provide examples of potential solutions in the form of innovative instrumentation, automation, and the application of existing methodology to inform and educate the audience about advances in sample preparation.
Speakers:
Dr Giorgio Blom - AstraZeneca
Dr Michelle Case - Bristol Myers Squibb
Dr Paola Ferrini - GlaxoSmithKline
Dr Joanne Laukart - Mettler Toledo
Dr Antonio Moreno-Herrera - AstraZeneca
Dr Adele Patterson - Bristol-Myers Squibb
DETAILS
Thursday 24th March 2022
Challenges in the Development of Drug Delivery Devices
VIRTUAL EVENT: 1pm-4:45pm GMT
Drug-Device combination products such as inhalers, nasal sprays and autoinjectors present a range of unique challenges for their successful development and analysis. Effective performance testing is critical for understanding the quality of these products, with critical quality attributes often limited by device performance as much as traditional chemical stability trends.
In this event our expert speakers will discuss the current trends in the analysis of these complex products. Topics will include test automation, current inhaled in-vitro bioequivalence techniques, and the latest regulatory perspectives from the MHRA.
Speakers:
Mike Bridge - Astech Projects
Paul Graham - Paul Graham Pharma Consulting
David Harris - Cambridge Healthcare Innovations
Shah Jahan - Astech Projects
Mark Parry - Intertek
Dr John Pritchard - Inspiring Strategies
Dr Marion Westwood - MHRA
DETAILS
Challenges in the Development of Drug Delivery Devices
VIRTUAL EVENT: 1pm-4:45pm GMT
Drug-Device combination products such as inhalers, nasal sprays and autoinjectors present a range of unique challenges for their successful development and analysis. Effective performance testing is critical for understanding the quality of these products, with critical quality attributes often limited by device performance as much as traditional chemical stability trends.
In this event our expert speakers will discuss the current trends in the analysis of these complex products. Topics will include test automation, current inhaled in-vitro bioequivalence techniques, and the latest regulatory perspectives from the MHRA.
Speakers:
Mike Bridge - Astech Projects
Paul Graham - Paul Graham Pharma Consulting
David Harris - Cambridge Healthcare Innovations
Shah Jahan - Astech Projects
Mark Parry - Intertek
Dr John Pritchard - Inspiring Strategies
Dr Marion Westwood - MHRA
DETAILS
Thursday 9th December 2021
Regulatory Hot Topics VI
VIRTUAL EVENT : 1pm-4:30pm (UK GMT)
This symposium will address issues and challenges associated with the implementation of new and emerging guidelines. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on various key emerging topics.
An excellent opportunity to learn from expert speakers involved in the development of the guidances on these key topics.
Speakers:
Anthony Barker - AstraZeneca
Dr Joel Bercu - Gilead
Dr Alistair Gibb - MHRA & BP Commission member
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Kevin Hughes - Colorcon
Dr Jasvinder Singh - MHRA
Prof Ricky Wildman - University of Nottingham
DETAILS
Regulatory Hot Topics VI
VIRTUAL EVENT : 1pm-4:30pm (UK GMT)
This symposium will address issues and challenges associated with the implementation of new and emerging guidelines. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on various key emerging topics.
An excellent opportunity to learn from expert speakers involved in the development of the guidances on these key topics.
Speakers:
Anthony Barker - AstraZeneca
Dr Joel Bercu - Gilead
Dr Alistair Gibb - MHRA & BP Commission member
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Kevin Hughes - Colorcon
Dr Jasvinder Singh - MHRA
Prof Ricky Wildman - University of Nottingham
DETAILS
Wednesday 17th November 2021
The JPAG pharmaceutical analysis research awards 2021
VIRTUAL EVENT : 1pm-4:45pm (UK GMT)
JPAG presents the pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Registration is free for all students, early career stage scientists and their supervisors/managers, but we highly encourage students and early career stage scientists delegates to submit an abstract for poster or oral presentation to this exciting annual JPAG event.
The deadline for submission of abstracts has now passed
Keynote speaker: Prof David Cowan OBE FKC FRPharmS FRSB, King's College London
Titie: A 30 minute snapshot of highlights in the career of a Pharmaceutical Analyst
In addition, held on-line one day before this awards Symposium, there will be a Careers Fair with the opportunity to meet on-line with big industry pharma and other key contacts and take advantage of the great networking opportunities. This could be the event to provide a step-change to your professional career. Your future employer could be here.
Further details on both the awards symposium and the careers fair will appear here soon.
Speakers:
Prof David Cowan - King's College London
DETAILS
The JPAG pharmaceutical analysis research awards 2021
VIRTUAL EVENT : 1pm-4:45pm (UK GMT)
JPAG presents the pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Registration is free for all students, early career stage scientists and their supervisors/managers, but we highly encourage students and early career stage scientists delegates to submit an abstract for poster or oral presentation to this exciting annual JPAG event.
The deadline for submission of abstracts has now passed
Keynote speaker: Prof David Cowan OBE FKC FRPharmS FRSB, King's College London
Titie: A 30 minute snapshot of highlights in the career of a Pharmaceutical Analyst
In addition, held on-line one day before this awards Symposium, there will be a Careers Fair with the opportunity to meet on-line with big industry pharma and other key contacts and take advantage of the great networking opportunities. This could be the event to provide a step-change to your professional career. Your future employer could be here.
Further details on both the awards symposium and the careers fair will appear here soon.
Speakers:
Prof David Cowan - King's College London
DETAILS
Tuesday 16th November 2021
The JPAG pharmaceutical analysis careers fair 2021
VIRTUAL EVENT : 12:30pm-5pm (UK GMT)
JPAG presents the pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry.
We will be holding a Networking and Careers Fair with the opportunity to meet on-line with big industry pharma and other key contacts and take advantage of the great networking opportunities. This could be the event to provide a step-change to your professional career. Your future employer could be here.
This event will be held on-line on the day before a symposium for our major awards, so please also take a look at that also.
Details for both the careers fair and the awards event will appear here soon.
DETAILS
The JPAG pharmaceutical analysis careers fair 2021
VIRTUAL EVENT : 12:30pm-5pm (UK GMT)
JPAG presents the pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry.
We will be holding a Networking and Careers Fair with the opportunity to meet on-line with big industry pharma and other key contacts and take advantage of the great networking opportunities. This could be the event to provide a step-change to your professional career. Your future employer could be here.
This event will be held on-line on the day before a symposium for our major awards, so please also take a look at that also.
Details for both the careers fair and the awards event will appear here soon.
DETAILS
Thursday 7th October 2021
The reality of ATMP delivery: pharmacy learning and future developments
VIRTUAL EVENT : 10am-4:20pm (UK BST)
This is the second one day Pan UK Pharmacy Working Group for ATMPs / JPAG conference, this time to be held virtually.
Advanced Therapy Medicinal Products (ATMPs) have revolutionised the treatment of some diseases, particularly those which were previously regarded as intractable to treatment and cure. ATMPs are biological medicines and can be defined by four main categories; in-vivo gene therapies, ex-vivo gene therapies, somatic cellular therapies and tissue engineered products.
As increasing numbers of ATMPs are now being seen through clinical trials and acquiring marketing authorisations.
This joint JPAG and Pan UK Pharmacy Working Group for ATMPs symposium will inform and educate the audience about hot topics in the ATMP world.
Speakers:
Dr Owen Bain - NHS Royal Free Hospital
Anne Black - Newcastle Upon Tyne Hospitals NHS Foundation Trust
David Caulfield - Newcastle Hospitals
Jackie Chappell - King's College Hospital NHS Foundation Trust
Damian Child - Sheffield Teaching Hospital
Amisha Desai - University Hospitals Birmingham NHS Foundation Trust
Hayley Dixey - Senior GCP Inspector MHRA
Ben Doak - National Senior Programme of Care Manager, Innovative Treatments, NHSEI
Dr Nia Evans - University Hospital of Wales
Imran Kausar - Novartis Gene Therapies
Dr Cathy McKenzie - King's College Hospital
Lynn Morrison - Greater Glasgow & Clyde
Dr Rachel Palmer - University Hospitals Bristol & Weston NHS Foundation Trust
Ian Rees - MHRA
Dr Ceri Roberts - NHSBT
Dr Justine Scanlan - Head of Specialist Pharmacy Service
Nisha Shaunak - Guys & St Thomas NHS Foundation Trust
John Spoors - Head of Commercial Medicines Policy Analysis, NHSEI
Alice Tam - The Royal Marsden
Prof Neil Watson - Newcastle Hospitals & Director, Northern Alliance Advanced Therapies Treatment Centre (NA-ATC)
DETAILS
The reality of ATMP delivery: pharmacy learning and future developments
VIRTUAL EVENT : 10am-4:20pm (UK BST)
This is the second one day Pan UK Pharmacy Working Group for ATMPs / JPAG conference, this time to be held virtually.
Advanced Therapy Medicinal Products (ATMPs) have revolutionised the treatment of some diseases, particularly those which were previously regarded as intractable to treatment and cure. ATMPs are biological medicines and can be defined by four main categories; in-vivo gene therapies, ex-vivo gene therapies, somatic cellular therapies and tissue engineered products.
As increasing numbers of ATMPs are now being seen through clinical trials and acquiring marketing authorisations.
This joint JPAG and Pan UK Pharmacy Working Group for ATMPs symposium will inform and educate the audience about hot topics in the ATMP world.
Speakers:
Dr Owen Bain - NHS Royal Free Hospital
Anne Black - Newcastle Upon Tyne Hospitals NHS Foundation Trust
David Caulfield - Newcastle Hospitals
Jackie Chappell - King's College Hospital NHS Foundation Trust
Damian Child - Sheffield Teaching Hospital
Amisha Desai - University Hospitals Birmingham NHS Foundation Trust
Hayley Dixey - Senior GCP Inspector MHRA
Ben Doak - National Senior Programme of Care Manager, Innovative Treatments, NHSEI
Dr Nia Evans - University Hospital of Wales
Imran Kausar - Novartis Gene Therapies
Dr Cathy McKenzie - King's College Hospital
Lynn Morrison - Greater Glasgow & Clyde
Dr Rachel Palmer - University Hospitals Bristol & Weston NHS Foundation Trust
Ian Rees - MHRA
Dr Ceri Roberts - NHSBT
Dr Justine Scanlan - Head of Specialist Pharmacy Service
Nisha Shaunak - Guys & St Thomas NHS Foundation Trust
John Spoors - Head of Commercial Medicines Policy Analysis, NHSEI
Alice Tam - The Royal Marsden
Prof Neil Watson - Newcastle Hospitals & Director, Northern Alliance Advanced Therapies Treatment Centre (NA-ATC)
DETAILS
Thursday 1st July 2021
Aseptic manufacturing
Virtual meeting (1-3:40pm UK BST)
Steriles manufacturing remains one of the most challenging areas of the pharmaceutical industry from both a compliance and a technical perspective. The regulatory expectations continue to evolve, however slowly and new technology has the potential to massively change ways of working.
This meeting is a must for all those in senior roles, QPs and anyone who has an eye on the future in the sector.
Speakers:
Alan Heavey - Sterilization Solutions
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Alan Moon - MHRA
Danielle Mulqueen - Jazz Pharmaceuticals
Simon Phillips - Nova Laboratories
Dr Birte Scharf - F Ziel GmbH
DETAILS
Aseptic manufacturing
Virtual meeting (1-3:40pm UK BST)
Steriles manufacturing remains one of the most challenging areas of the pharmaceutical industry from both a compliance and a technical perspective. The regulatory expectations continue to evolve, however slowly and new technology has the potential to massively change ways of working.
This meeting is a must for all those in senior roles, QPs and anyone who has an eye on the future in the sector.
Speakers:
Alan Heavey - Sterilization Solutions
Dr Lisa Hinchliffe - Regulatory CMC Consultant
Alan Moon - MHRA
Danielle Mulqueen - Jazz Pharmaceuticals
Simon Phillips - Nova Laboratories
Dr Birte Scharf - F Ziel GmbH
DETAILS
Thursday 17th June 2021
Risk assessment: Opportunities and challenges
Mini-symposium VIRTUAL EVENT : 1pm-2:45pm (UK BST)
Risk assessment plays such a pivotal role in modern quality by design (QbD), pharmaceutical development and life cycle management.
This mini symposium will look at risk assessment through the lens of three topical case studies looking at (i) a potential stock out issue, (ii) the current nitrosamine issues and (iii) risk assessment supporting analytical QbD.
Speakers:
Dr David Elder - JPAG/Consultant
Derek Lonergan - Jazz Pharmaceuticals
Steven Mount - AstraZeneca
DETAILS
Risk assessment: Opportunities and challenges
Mini-symposium VIRTUAL EVENT : 1pm-2:45pm (UK BST)
Risk assessment plays such a pivotal role in modern quality by design (QbD), pharmaceutical development and life cycle management.
This mini symposium will look at risk assessment through the lens of three topical case studies looking at (i) a potential stock out issue, (ii) the current nitrosamine issues and (iii) risk assessment supporting analytical QbD.
Speakers:
Dr David Elder - JPAG/Consultant
Derek Lonergan - Jazz Pharmaceuticals
Steven Mount - AstraZeneca
DETAILS
Thursday 13th May 2021
Biological potency
VIRTUAL EVENT : 1pm-3:30pm (UK BST)
Biological activity is a critical quality attribute for biological products. As this class of therapeutics expands and becomes more complex, with the growth of antibody-drug conjugates and cell and gene therapies for example, there are increasing challenges in developing scientifically relevant biological potency assays suitable for each stage of the product life cycle and, in particular, assays that are sufficiently robust for use in the GMP QC environment supporting clinical and commercial manufacturing.
This meeting will consider approaches to overcoming those challenges, including strategies for transitioning assays from R&D into the QC environment, application of new technologies to improve robustness of assays and methods for measuring the potency of cell therapies.
Speakers:
Dr Emma Bowen - Covance
Dr Monica Gunetti - OPBG
Dr Vijay Jethwa - Biologics Consulting
Dr Christiane Niederlaender - Parexel
Dr Ann Yellowlees - Quantics Biostatistics
DETAILS
Biological potency
VIRTUAL EVENT : 1pm-3:30pm (UK BST)
Biological activity is a critical quality attribute for biological products. As this class of therapeutics expands and becomes more complex, with the growth of antibody-drug conjugates and cell and gene therapies for example, there are increasing challenges in developing scientifically relevant biological potency assays suitable for each stage of the product life cycle and, in particular, assays that are sufficiently robust for use in the GMP QC environment supporting clinical and commercial manufacturing.
This meeting will consider approaches to overcoming those challenges, including strategies for transitioning assays from R&D into the QC environment, application of new technologies to improve robustness of assays and methods for measuring the potency of cell therapies.
Speakers:
Dr Emma Bowen - Covance
Dr Monica Gunetti - OPBG
Dr Vijay Jethwa - Biologics Consulting
Dr Christiane Niederlaender - Parexel
Dr Ann Yellowlees - Quantics Biostatistics
DETAILS
Thursday 25th March 2021
Stability V: Challenges of in-use stability demonstration
VIRTUAL EVENT : 1pm-4pm (UK GMT)
Continuing our successful series of stability meetings, this event is essential for anyone concerned with the management and assessment of drug stability in-use. We have a group of expert speakers on in-use stability topics from the regulator, the industry and the NHS end user to give a background of their in-use stability perspectives and provide examples of practical issues they have had to face in their every day work. This is followed up by the speakers forming a panel for a workshop style question discussion.
Speakers:
Miles Ambler - GlaxoSmithKline
Bridget Bulwer - Glycostem
Dr Laura Davies - Newcastle upon Tyne Hospitals NHS Foundation Trust
Dr Paul Marshall - Jazz Pharmaceuticals
DETAILS
Stability V: Challenges of in-use stability demonstration
VIRTUAL EVENT : 1pm-4pm (UK GMT)
Continuing our successful series of stability meetings, this event is essential for anyone concerned with the management and assessment of drug stability in-use. We have a group of expert speakers on in-use stability topics from the regulator, the industry and the NHS end user to give a background of their in-use stability perspectives and provide examples of practical issues they have had to face in their every day work. This is followed up by the speakers forming a panel for a workshop style question discussion.
Speakers:
Miles Ambler - GlaxoSmithKline
Bridget Bulwer - Glycostem
Dr Laura Davies - Newcastle upon Tyne Hospitals NHS Foundation Trust
Dr Paul Marshall - Jazz Pharmaceuticals
DETAILS
Thursday 25th March 2021
Annual General Meeting
Royal Society of Chemistry, London
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 4.30 pm
Click the button below for the
AGENDA and other documents and to
JOIN THE MEETING.
DETAILS
Annual General Meeting
Royal Society of Chemistry, London
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 4.30 pm
Click the button below for the
AGENDA and other documents and to
JOIN THE MEETING.
DETAILS
Thursday 3rd December 2020
Data integrity II
VIRTUAL EVENT : 1pm-4pm (UK GMT)
Data integrity still continues to be a very hot topic for Industry and regulators alike. Data integrity still appears in the list of top five audit findings. This is a must attend meeting for anyone involved in addressing issues and challenges associated with data integrity.
Speakers:
Dr Ian Clegg - Bruker
Vanessa Grant - AstraZeneca
Martin Hall - Covance
Colin Robinson - Pfizer
Jim Silva - Pfizer
Jason Wakelin-Smith - MHRA
Greg Webber - GlaxoSmithKline
DETAILS
Data integrity II
VIRTUAL EVENT : 1pm-4pm (UK GMT)
Data integrity still continues to be a very hot topic for Industry and regulators alike. Data integrity still appears in the list of top five audit findings. This is a must attend meeting for anyone involved in addressing issues and challenges associated with data integrity.
Speakers:
Dr Ian Clegg - Bruker
Vanessa Grant - AstraZeneca
Martin Hall - Covance
Colin Robinson - Pfizer
Jim Silva - Pfizer
Jason Wakelin-Smith - MHRA
Greg Webber - GlaxoSmithKline
DETAILS
Thursday 3rd December 2020
Annual General Meeting
VIRTUAL EVENT
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 4.30 pm
Click the button below for
the AGENDA and more documents and to JOIN THE MEETING.
DETAILS
Annual General Meeting
VIRTUAL EVENT
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 4.30 pm
Click the button below for
the AGENDA and more documents and to JOIN THE MEETING.
DETAILS
Tuesday 17th November 2020
JPAG pharmaceutical analysis research awards 2020
VIRTUAL EVENT : 1pm-4pm (UK BST)
JPAG presents the fourth pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Registration is free for all students, early career stage scientists and their supervisors/managers, but we highly encourage students and early career stage scientists delegates to submit an abstract for poster or oral presentation to this exciting annual JPAG event.
The deadline for submission of abstracts has now passed
This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
Speakers:
Dr Paul Royall - King's College London
DETAILS
JPAG pharmaceutical analysis research awards 2020
VIRTUAL EVENT : 1pm-4pm (UK BST)
JPAG presents the fourth pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Registration is free for all students, early career stage scientists and their supervisors/managers, but we highly encourage students and early career stage scientists delegates to submit an abstract for poster or oral presentation to this exciting annual JPAG event.
The deadline for submission of abstracts has now passed
This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
Speakers:
Dr Paul Royall - King's College London
DETAILS
Thursday 8th October 2020
Regulatory Hot Topics V
VIRTUAL EVENT : 1pm-4pm (UK BST)
This virtual symposium will address issues and challenges associated with the implementation of new and emerging guidelines. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on various key emerging topics.
An excellent opportunity to learn from expert speakers involved in the development of the guidances on these key topics.
Speakers:
Dr Karin Boon - MHRA
James Drinkwater - Pharmaceutical and Healthcare Sciences Society
Dr David Elder - JPAG/Consultant
Dr James Harvey - GlaxoSmithKline
Dr Andrew Teasdale - AstraZeneca
Dr Lars Weidolf - AstraZeneca
DETAILS
Regulatory Hot Topics V
VIRTUAL EVENT : 1pm-4pm (UK BST)
This virtual symposium will address issues and challenges associated with the implementation of new and emerging guidelines. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on various key emerging topics.
An excellent opportunity to learn from expert speakers involved in the development of the guidances on these key topics.
Speakers:
Dr Karin Boon - MHRA
James Drinkwater - Pharmaceutical and Healthcare Sciences Society
Dr David Elder - JPAG/Consultant
Dr James Harvey - GlaxoSmithKline
Dr Andrew Teasdale - AstraZeneca
Dr Lars Weidolf - AstraZeneca
DETAILS
Thursday 2nd July 2020
Assuring the quality of radio-labelled products from clinical trials to commercialisation
VIRTUAL EVENT : 1pm-4pm (UK BST)
The use of radiolabelled materials in clinical trial, therapeutic and diagnostic applications presents many specialised challenges to assure their fitness for intended purpose. This symposium will examine the uses of radiolabelled materials, key regulatory requirements and best practices to assure their quality in clinical trials or commercialisation.
We gratefully acknowledge the sponsorship of Eurofins Selcia for this event.
Low price £50
Speakers:
Dr Marie Croft - Pharmaron
Dr Philippe Dasse - Advanced Accelerator Applications
Dr Simona de Robertis - MHRA
Dr Neil Geach - Selcia
Victoria Gibson - Guys and St Thomas Hospital
Ian Harwood - MHRA
Justin Holland - Quotient Sciences
Jordi Vall-Llossera - Advanced Accelerator Applications
DETAILS
Assuring the quality of radio-labelled products from clinical trials to commercialisation
VIRTUAL EVENT : 1pm-4pm (UK BST)
The use of radiolabelled materials in clinical trial, therapeutic and diagnostic applications presents many specialised challenges to assure their fitness for intended purpose. This symposium will examine the uses of radiolabelled materials, key regulatory requirements and best practices to assure their quality in clinical trials or commercialisation.
We gratefully acknowledge the sponsorship of Eurofins Selcia for this event.
Low price £50
Speakers:
Dr Marie Croft - Pharmaron
Dr Philippe Dasse - Advanced Accelerator Applications
Dr Simona de Robertis - MHRA
Dr Neil Geach - Selcia
Victoria Gibson - Guys and St Thomas Hospital
Ian Harwood - MHRA
Justin Holland - Quotient Sciences
Jordi Vall-Llossera - Advanced Accelerator Applications
DETAILS
Thursday 7th May 2020
ICH Q3E (Extractables and Leachables): setting the scene
VIRTUAL EVENT : 1pm-4pm (UK BST)
ICH Q3E (Extractables and Leachables) has been adopted by the ICH governing body as ICH Q3E and will now progress through the various ICH stages that will culminate as an international harmonised guideline. This meeting will be an important event in understanding and trying to influence the outcome of the ICH Q3E proceedings.
Introductory Low Price: £25
Speakers:
Jason Creasey - Maven E&L
Dr David Elder - JPAG/Consultant
Dr Andrew Feilden - Hall Analytical
Dr Andrew Teasdale - AstraZeneca
Chris Waine - bibra toxicology advice and consulting
Dr Carsten Worsøe - Novo Nordisk
DETAILS
ICH Q3E (Extractables and Leachables): setting the scene
VIRTUAL EVENT : 1pm-4pm (UK BST)
ICH Q3E (Extractables and Leachables) has been adopted by the ICH governing body as ICH Q3E and will now progress through the various ICH stages that will culminate as an international harmonised guideline. This meeting will be an important event in understanding and trying to influence the outcome of the ICH Q3E proceedings.
Introductory Low Price: £25
Speakers:
Jason Creasey - Maven E&L
Dr David Elder - JPAG/Consultant
Dr Andrew Feilden - Hall Analytical
Dr Andrew Teasdale - AstraZeneca
Chris Waine - bibra toxicology advice and consulting
Dr Carsten Worsøe - Novo Nordisk
DETAILS
Thursday 6th February 2020
In silico techniques
Royal Society of Chemistry, London
As the pace of pharmaceutical development accelerates, and organisations look to reduce timelines in all parts of the discovery and development process, opportunities emerge for the greater use of in silico tools to reduce the demand for materials or experimental tests. This meeting will showcase a range of applications of in silico modelling, whether for prediction of properties via first principles modelling, or applying contemporary tools for data-driven modelling. Examples covering chromatography and the physical form of drugs will be discussed, as well as tools for prediction of the key performance properties such as toxicology, dissolution and stability.
Speakers:
Dr Edward Close - Process Systems Enterprise
Prof Mel Euerby - Shimadzu
Dr Andy Maloney - Cambridge Crystallographic Data Centre
Dr James Mann - AstraZeneca
Dr Ed Milton-Harris - ACD/Labs
Dr Ghazala Sadiq - Cambridge Crystallographic Data Centre
Dr Garry Scrivens - Pfizer
Dr Patrick Wray - Bristol-Myers Squibb
DETAILS
In silico techniques
Royal Society of Chemistry, London
As the pace of pharmaceutical development accelerates, and organisations look to reduce timelines in all parts of the discovery and development process, opportunities emerge for the greater use of in silico tools to reduce the demand for materials or experimental tests. This meeting will showcase a range of applications of in silico modelling, whether for prediction of properties via first principles modelling, or applying contemporary tools for data-driven modelling. Examples covering chromatography and the physical form of drugs will be discussed, as well as tools for prediction of the key performance properties such as toxicology, dissolution and stability.
Speakers:
Dr Edward Close - Process Systems Enterprise
Prof Mel Euerby - Shimadzu
Dr Andy Maloney - Cambridge Crystallographic Data Centre
Dr James Mann - AstraZeneca
Dr Ed Milton-Harris - ACD/Labs
Dr Ghazala Sadiq - Cambridge Crystallographic Data Centre
Dr Garry Scrivens - Pfizer
Dr Patrick Wray - Bristol-Myers Squibb
DETAILS
Thursday 5th December 2019
Regulatory hot topics IV
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with the implementation of new and emerging guidelines. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on various key emerging topics.
An excellent opportunity to learn from expert speakers involved in the development of the guidances on these key topics.
Speakers:
Dr Cristiana Campa - GlaxoSmithKline
Dr David Elder - JPAG/Consultant
Dr James Harvey - GlaxoSmithKline
Prof David Littlejohn - University of Strathclyde
Dr Helmut Rockstroh - Roche
Dr David Snodin - Xiphora Biopharma Consulting
Dr David Yeo - Lhasa
DETAILS
Regulatory hot topics IV
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with the implementation of new and emerging guidelines. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on various key emerging topics.
An excellent opportunity to learn from expert speakers involved in the development of the guidances on these key topics.
Speakers:
Dr Cristiana Campa - GlaxoSmithKline
Dr David Elder - JPAG/Consultant
Dr James Harvey - GlaxoSmithKline
Prof David Littlejohn - University of Strathclyde
Dr Helmut Rockstroh - Roche
Dr David Snodin - Xiphora Biopharma Consulting
Dr David Yeo - Lhasa
DETAILS
Tuesday 26th November 2019
The pharmaceutical analysis research awards and careers symposium 2019
Royal Society of Chemistry, London
JPAG presents the third pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Registration is free for all students, early career stage scientists and their supervisors/managers, but we highly encourage students and early career stage scientists delegates to submit an abstract for poster or oral presentation to this exciting annual JPAG event.
The deadline for submission of abstracts has now passed
In addition, there will be "meet the editor" sessions for advice on getting your research published,a Networking and Careers Fair, open to undergraduate and postgraduate students well as early career stage scientists, with the opportunity to meet with big industry pharma and other key contacts and take advantage of the great networking opportunities.
This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
There will be a presentation from the Royal Society of Chemistry's Careers Specialists Dr Robert Bowles and Sarah Salter on 'Job hunting in the pharmaceutical industry'. They will also conduct a 'CV Surgery' for RSC members; these are one-to-one discussions for members to find out how to present a good CV. So be sure to bring your CV along!
Registration will open at 8:30am for a 9am start, and the day will end with a Careers and Networking wine reception starting at 6pm.
Speakers:
Prof Abdul Basit - University College London
Prof Michael Heinrich - University College London
Dr Alice Barker - Royal Society of Chemistry
Dr Robert Bowles - Royal Society of Chemistry
Sarah Salter - Royal Society of Chemistry
DETAILS
The pharmaceutical analysis research awards and careers symposium 2019
Royal Society of Chemistry, London
JPAG presents the third pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Registration is free for all students, early career stage scientists and their supervisors/managers, but we highly encourage students and early career stage scientists delegates to submit an abstract for poster or oral presentation to this exciting annual JPAG event.
The deadline for submission of abstracts has now passed
In addition, there will be "meet the editor" sessions for advice on getting your research published,a Networking and Careers Fair, open to undergraduate and postgraduate students well as early career stage scientists, with the opportunity to meet with big industry pharma and other key contacts and take advantage of the great networking opportunities.
This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
There will be a presentation from the Royal Society of Chemistry's Careers Specialists Dr Robert Bowles and Sarah Salter on 'Job hunting in the pharmaceutical industry'. They will also conduct a 'CV Surgery' for RSC members; these are one-to-one discussions for members to find out how to present a good CV. So be sure to bring your CV along!
Registration will open at 8:30am for a 9am start, and the day will end with a Careers and Networking wine reception starting at 6pm.
Speakers:
Prof Abdul Basit - University College London
Prof Michael Heinrich - University College London
Dr Alice Barker - Royal Society of Chemistry
Dr Robert Bowles - Royal Society of Chemistry
Sarah Salter - Royal Society of Chemistry
DETAILS
Thursday 10th October 2019
Mutagenic Impurities
Royal Society of Chemistry, London
This one-day joint symposium with the RSC Toxicology group will address issues and challenges associated with mutagenic impurities. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on how the guidelines are being interpreted by regulators and pharmacopoeias. An overview of the latest approaches to purging (i.e. ICH M7 option 4) from the Mirabilis consortium, several analytical case studies showing state-of-the-art approaches to the analysis of MIs, a case study showing how the mutagenic risk assessment (MRA) is translated into CTD format for subsequent regulatory filing. There will also be a timely update on the Valsartan contamination issue: what happened, why it happened and how it is being controlled.
An excellent opportunity to learn from expert speakers involved in the interpretation and application of these key topics.
Speakers:
Dr Michael Burns - Lhasa
Mark Harrison - AstraZeneca
Dr George Johnson - Swansea University
Richard Jones - GlaxoSmithKline
Dr Henry Stemplewski - MHRA
Dr Andrew Teasdale - AstraZeneca
Dr Mike Urquhart - GlaxoSmithKline
DETAILS
Mutagenic Impurities
Royal Society of Chemistry, London
This one-day joint symposium with the RSC Toxicology group will address issues and challenges associated with mutagenic impurities. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on how the guidelines are being interpreted by regulators and pharmacopoeias. An overview of the latest approaches to purging (i.e. ICH M7 option 4) from the Mirabilis consortium, several analytical case studies showing state-of-the-art approaches to the analysis of MIs, a case study showing how the mutagenic risk assessment (MRA) is translated into CTD format for subsequent regulatory filing. There will also be a timely update on the Valsartan contamination issue: what happened, why it happened and how it is being controlled.
An excellent opportunity to learn from expert speakers involved in the interpretation and application of these key topics.
Speakers:
Dr Michael Burns - Lhasa
Mark Harrison - AstraZeneca
Dr George Johnson - Swansea University
Richard Jones - GlaxoSmithKline
Dr Henry Stemplewski - MHRA
Dr Andrew Teasdale - AstraZeneca
Dr Mike Urquhart - GlaxoSmithKline
DETAILS
Thursday 19th September 2019
Advancements in pharmaceutical QC testing: dissolution and QbD testing
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with dissolution and analytical QbD. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been actively involved in shaping the various guidances - and the peer group in an open forum. Topics will include
* Current/future state of dissolution testing
*Statistical modelling in predicting dissolution issues
* Introduction of meaningful pharmacopoeial dissolution specifications for modified release products
* The Role of Quality by Design in analytical testing
* Measurement uncertainty in analytical testing
Speakers:
Dr Karin Boon - MHRA
Dr Philip Borman - GlaxoSmithKline
Stephen Maddocks - MHRA
Dr James Mann - AstraZeneca
Elena Razzano - MHRA
Dr Garry Scrivens - Pfizer
Prof Clive Wilson - University of Strathclyde
Stephen Young - MHRA
DETAILS
Advancements in pharmaceutical QC testing: dissolution and QbD testing
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with dissolution and analytical QbD. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been actively involved in shaping the various guidances - and the peer group in an open forum. Topics will include
* Current/future state of dissolution testing
*Statistical modelling in predicting dissolution issues
* Introduction of meaningful pharmacopoeial dissolution specifications for modified release products
* The Role of Quality by Design in analytical testing
* Measurement uncertainty in analytical testing
Speakers:
Dr Karin Boon - MHRA
Dr Philip Borman - GlaxoSmithKline
Stephen Maddocks - MHRA
Dr James Mann - AstraZeneca
Elena Razzano - MHRA
Dr Garry Scrivens - Pfizer
Prof Clive Wilson - University of Strathclyde
Stephen Young - MHRA
DETAILS
Thursday 9th May 2019
Assuring the quality of medicines III; aseptic products
Royal Society of Chemistry, London
The quality of Aseptic products is the most critical challenge in the pharmaceutical industry. It covers those medicinal products that cannot be terminally sterilised, the majority of new injectable IMPs and all gene therapy and ATMPs. In addition, 2019 is a vitally important year as the revised Annex 1 becomes globally implemented and provides a host of challenges for the industry trying to implement it. JPAG has been able to bring together a unique and almost unparalleled group of speakers in a programme that tries to cover the hottest topics in this field.
There will be adequate time after each presentation to discuss case studies and practical implications.
Speakers:
tim sandle -
Dr Paul Beckett - Merck Millipore
James Drinkwater - Pharmaceutical and Healthcare Sciences Society
Dawn Hiles - Newcastle Cellular Therapies Facility, International Centre for Life
Alan Moon - MHRA
Di Morris - GlaxoSmithKline
DETAILS
Assuring the quality of medicines III; aseptic products
Royal Society of Chemistry, London
The quality of Aseptic products is the most critical challenge in the pharmaceutical industry. It covers those medicinal products that cannot be terminally sterilised, the majority of new injectable IMPs and all gene therapy and ATMPs. In addition, 2019 is a vitally important year as the revised Annex 1 becomes globally implemented and provides a host of challenges for the industry trying to implement it. JPAG has been able to bring together a unique and almost unparalleled group of speakers in a programme that tries to cover the hottest topics in this field.
There will be adequate time after each presentation to discuss case studies and practical implications.
Speakers:
tim sandle
Dr Paul Beckett - Merck Millipore
James Drinkwater - Pharmaceutical and Healthcare Sciences Society
Dawn Hiles - Newcastle Cellular Therapies Facility, International Centre for Life
Alan Moon - MHRA
Di Morris - GlaxoSmithKline
DETAILS
Thursday 21st March 2019
Stability IV: Developments in stability testing and evaluation
Royal Society of Chemistry, London
Continuing our successful series of stability meetings, this is an essential event for anyone concerned with the management and assessment of drug stability:
• Hear from individuals involved in the regulation and inspection of stability and GDP
• Learn from industry experts on scientific developments in stability study design and interpretation
• Debate practical issues for evaluating data and predicting stability
• Examine ways to improve compliance and productivity in stability testing
• Network with other professionals and exhibitors
Speakers:
Conor Jamieson - Sandwell and West Birmingham NHS Trust
Dr Jonathan Bright - AstraZeneca
John Cleverley - Clarivate Analytics
Dr Paul Fullerton - AMRI
Dr Rachel Orr - GlaxoSmithKline
Dr Garry Scrivens - Pfizer
Susan Smith - AstraZeneca
Dr Maria Krisch - Freethink Technologies Inc
DETAILS
Stability IV: Developments in stability testing and evaluation
Royal Society of Chemistry, London
Continuing our successful series of stability meetings, this is an essential event for anyone concerned with the management and assessment of drug stability:
• Hear from individuals involved in the regulation and inspection of stability and GDP
• Learn from industry experts on scientific developments in stability study design and interpretation
• Debate practical issues for evaluating data and predicting stability
• Examine ways to improve compliance and productivity in stability testing
• Network with other professionals and exhibitors
Speakers:
Conor Jamieson - Sandwell and West Birmingham NHS Trust
Dr Jonathan Bright - AstraZeneca
John Cleverley - Clarivate Analytics
Dr Paul Fullerton - AMRI
Dr Rachel Orr - GlaxoSmithKline
Dr Garry Scrivens - Pfizer
Susan Smith - AstraZeneca
Dr Maria Krisch - Freethink Technologies Inc
DETAILS
Thursday 21st March 2019
Annual General Meeting
Royal Society of Chemistry, London
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 9.30 am
Click here to see the Agenda
Click here to see the Minutes from last year
DETAILS
Annual General Meeting
Royal Society of Chemistry, London
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 9.30 am
Click here to see the Agenda
Click here to see the Minutes from last year
DETAILS
Thursday 7th February 2019
Accelerated development and approval
Royal Society of Chemistry, London
This symposium offers a diverse programme of talks to look at many facets of drug development programmes, and how analytical science can assist, or is impacted by, the desire to reduce the time taken to get a product to market.
Acceleration of drug development programmes is a common theme whether for smaller companies, or for the larger bio-pharmaceutical players. Reduced time for product development can lead to reduced process experience, fewer clinical batches and increasing the numbers of dependent activities that are run in parallel. Each of these factors may impact analytical scientists, whether in reduced time to develop methods and specifications, limited real-time product stability data, or in increased volume of samples that are generated in short periods of time.
Speakers:
Neil Clayton - Pfizer
Dr Paul Newby - GlaxoSmithKline
Dr Daniel OConnor - MHRA
Henk Poelman - PRA Health Sciences
Dr Matt Popkin - GlaxoSmithKline
Dr Przemek Stasica - GlaxoSmithKline
Dr Andrew Teasdale - AstraZeneca
Dr Helen Wheatcroft - AstraZeneca
DETAILS
Accelerated development and approval
Royal Society of Chemistry, London
This symposium offers a diverse programme of talks to look at many facets of drug development programmes, and how analytical science can assist, or is impacted by, the desire to reduce the time taken to get a product to market.
Acceleration of drug development programmes is a common theme whether for smaller companies, or for the larger bio-pharmaceutical players. Reduced time for product development can lead to reduced process experience, fewer clinical batches and increasing the numbers of dependent activities that are run in parallel. Each of these factors may impact analytical scientists, whether in reduced time to develop methods and specifications, limited real-time product stability data, or in increased volume of samples that are generated in short periods of time.
Speakers:
Neil Clayton - Pfizer
Dr Paul Newby - GlaxoSmithKline
Dr Daniel OConnor - MHRA
Henk Poelman - PRA Health Sciences
Dr Matt Popkin - GlaxoSmithKline
Dr Przemek Stasica - GlaxoSmithKline
Dr Andrew Teasdale - AstraZeneca
Dr Helen Wheatcroft - AstraZeneca
DETAILS
Thursday 6th December 2018
Regulatory Hot Topics III
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with the implementation of new and emerging guidelines. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on topics including elemental impurities, life-cycle management, DNA reactive (mutagenic) impurities, BCS-based biowavers, impurities in New Drug Substances, and the effect of MAPPS.
An excellent opportunity to learn from expert speakers involved in the development of the guidances on these key topics.
Speakers:
Dr James Butler - GlaxoSmithKline
Julia Claus - Pfizer
Dr Graham Cook - Pfizer
Dr James Harvey - GlaxoSmithKline
Kevin Hughes - Colorcon
Dr Frank Montgomery - AstraZeneca
Dr Matt Popkin - GlaxoSmithKline
Dr Helmut Rockstroh - Roche
Dr Andrew Teasdale - AstraZeneca
DETAILS
Regulatory Hot Topics III
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with the implementation of new and emerging guidelines. It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been very actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance on topics including elemental impurities, life-cycle management, DNA reactive (mutagenic) impurities, BCS-based biowavers, impurities in New Drug Substances, and the effect of MAPPS.
An excellent opportunity to learn from expert speakers involved in the development of the guidances on these key topics.
Speakers:
Dr James Butler - GlaxoSmithKline
Julia Claus - Pfizer
Dr Graham Cook - Pfizer
Dr James Harvey - GlaxoSmithKline
Kevin Hughes - Colorcon
Dr Frank Montgomery - AstraZeneca
Dr Matt Popkin - GlaxoSmithKline
Dr Helmut Rockstroh - Roche
Dr Andrew Teasdale - AstraZeneca
DETAILS
Tuesday 20th November 2018
The pharmaceutical analysis research awards and careers symposium 2018
Royal Society of Chemistry, London
Based on the great success of the inaugural meeting, JPAG presents the second pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Authors who submit an abstract that is accepted for presentation (oral or poster) will receive a complimentary registration.
The closing date for submission of abstracts has now passed
In addition, there will be a Networking and Careers Fair, open to undergraduate and postgraduate students well as early career stage scientists, with the opportunity to meet with big industry pharma and other key contacts and take advantage of the great networking opportunities.
This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
There will be a presentation from the Royal Society of Chemistry's Careers Specialists Julie Franklin and Sarah Salter on 'Job hunting in the pharmaceutical industry'. They will also conduct a 'CV Surgery' for RSC members; these are one-to-one discussions for members to find out how to present a good CV. So be sure to bring your CV along!
Registration will open at 8:30am for a 9am start, and the day will end with a Careers and Networking wine reception starting at 6pm.
There are just a few free places available. These are strictly for students. Go to Register now and use the Access code NOV111
Speakers:
Prof Luigi Martini - Royal Pharmaceutical Society
Julie Franklin - Royal Society of Chemistry
Sarah Salter - Royal Society of Chemistry
DETAILS
The pharmaceutical analysis research awards and careers symposium 2018
Royal Society of Chemistry, London
Based on the great success of the inaugural meeting, JPAG presents the second pharmaceutical analysis symposium for postgraduate students and early career stage scientists, including those in industry. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through oral and poster presentations. There will be a £1,000 first prize and £250 second prize for the best oral presentations as well as £200 first prize and two runner-up prizes of £100 for the best posters. Authors who submit an abstract that is accepted for presentation (oral or poster) will receive a complimentary registration.
The closing date for submission of abstracts has now passed
In addition, there will be a Networking and Careers Fair, open to undergraduate and postgraduate students well as early career stage scientists, with the opportunity to meet with big industry pharma and other key contacts and take advantage of the great networking opportunities.
This could be the event to provide a step-change to your professional career. Perhaps your future employer will be here.
There will be a presentation from the Royal Society of Chemistry's Careers Specialists Julie Franklin and Sarah Salter on 'Job hunting in the pharmaceutical industry'. They will also conduct a 'CV Surgery' for RSC members; these are one-to-one discussions for members to find out how to present a good CV. So be sure to bring your CV along!
Registration will open at 8:30am for a 9am start, and the day will end with a Careers and Networking wine reception starting at 6pm.
There are just a few free places available. These are strictly for students. Go to Register now and use the Access code NOV111
Speakers:
Prof Luigi Martini - Royal Pharmaceutical Society
Julie Franklin - Royal Society of Chemistry
Sarah Salter - Royal Society of Chemistry
DETAILS
Thursday 11th October 2018
Breaking down the barriers to widespread delivery of ATMPs
Royal Society of Chemistry, London
The aim of this meeting is inform the audience about the ATMP journey from concept to commercialisation - looking at regulatory hot topics for both GMP and GCP, challenges to hospital implementation, the role of Pharmacy, the role of the ATTC, ways to address the QP expertise deficit and give a forum for networking and discussion.
This programme will appeal to Chief Pharmacists, Clinical Trials Pharmacy Managers, Hospital Research and Development, sponsors, QPs, and member of the ATMP Manufacturing Community.
This meeting is organised in association with the RPS.
Speakers:
Jacqueline Barry - Catapult
Anne Black - Newcastle Upon Tyne Hospitals NHS Foundation Trust
David Caulfield - Newcastle upon Tyne Hospitals NHS Foundation Trust
Prof Mark Lowdell - University College London
Anthea Mould - NIHR
Ian Rees - MHRA
Prof Nicola Stoner - Oxford University Hospitals NHS Foundation Trust
Paula Walker - MHRA
DETAILS
Breaking down the barriers to widespread delivery of ATMPs
Royal Society of Chemistry, London
The aim of this meeting is inform the audience about the ATMP journey from concept to commercialisation - looking at regulatory hot topics for both GMP and GCP, challenges to hospital implementation, the role of Pharmacy, the role of the ATTC, ways to address the QP expertise deficit and give a forum for networking and discussion.
This programme will appeal to Chief Pharmacists, Clinical Trials Pharmacy Managers, Hospital Research and Development, sponsors, QPs, and member of the ATMP Manufacturing Community.
This meeting is organised in association with the RPS.
Speakers:
Jacqueline Barry - Catapult
Anne Black - Newcastle Upon Tyne Hospitals NHS Foundation Trust
David Caulfield - Newcastle upon Tyne Hospitals NHS Foundation Trust
Prof Mark Lowdell - University College London
Anthea Mould - NIHR
Ian Rees - MHRA
Prof Nicola Stoner - Oxford University Hospitals NHS Foundation Trust
Paula Walker - MHRA
DETAILS
Thursday 28th June 2018
Harmonisation and application of BCS-based Guidance
Royal Society of Chemistry, London
This symposium will look at the progress of the ICH M9 guidance (Biopharmaceutics Classification System (BCS)-Based Biowaivers) from a regulatory and industrial perspective; evaluating barriers to implementation from a solubility, permeability and dissolution perspective.
Speakers:
Dr Andreas Abend - Merck
Dr Bertil Abrahamsson - AstraZeneca
Dr James Butler - GlaxoSmithKline
Dr David Elder - JPAG/Consultant
Dr Nikoletta Fotaki - University of Bath
Dr James Mann - AstraZeneca
Dr Mark McAllister - Pfizer
Dr Henrike Potthast - BfARM
DETAILS
Harmonisation and application of BCS-based Guidance
Royal Society of Chemistry, London
This symposium will look at the progress of the ICH M9 guidance (Biopharmaceutics Classification System (BCS)-Based Biowaivers) from a regulatory and industrial perspective; evaluating barriers to implementation from a solubility, permeability and dissolution perspective.
Speakers:
Dr Andreas Abend - Merck
Dr Bertil Abrahamsson - AstraZeneca
Dr James Butler - GlaxoSmithKline
Dr David Elder - JPAG/Consultant
Dr Nikoletta Fotaki - University of Bath
Dr James Mann - AstraZeneca
Dr Mark McAllister - Pfizer
Dr Henrike Potthast - BfARM
DETAILS
Thursday 10th May 2018
From cradle to grave: the chromatographic (analytical) method life cycle
Royal Society of Chemistry, London
This meeting, jointly organised with the Chromatographic Society (Chrom Soc), will look to holistically examine the entire analytical method lifecycle. Each aspect of the cycle will be examined through the perspective of leading experts in each of these areas, aiming to give as a result a state-of-the-art perspective on each area.
Speakers:
Dr Sophie Bailes - AstraZeneca
Dr Claudio Brunelli - Pfizer
Prof Melissa Hanna-Brown - Pfizer
Dr Sibylle Heidelberger - SCIEX
Dr Katrin Liebelt - Novartis
Dr Alan McKeown - Advanced Chromatography Technologies
Shaun Pritchard - Agilent Technologies
Elena Razzano - MHRA
Josep Serret - Crawford Scientific
Dr Stuart Williams - Dove Analytics
DETAILS
From cradle to grave: the chromatographic (analytical) method life cycle
Royal Society of Chemistry, London
This meeting, jointly organised with the Chromatographic Society (Chrom Soc), will look to holistically examine the entire analytical method lifecycle. Each aspect of the cycle will be examined through the perspective of leading experts in each of these areas, aiming to give as a result a state-of-the-art perspective on each area.
Speakers:
Dr Sophie Bailes - AstraZeneca
Dr Claudio Brunelli - Pfizer
Prof Melissa Hanna-Brown - Pfizer
Dr Sibylle Heidelberger - SCIEX
Dr Katrin Liebelt - Novartis
Dr Alan McKeown - Advanced Chromatography Technologies
Shaun Pritchard - Agilent Technologies
Elena Razzano - MHRA
Josep Serret - Crawford Scientific
Dr Stuart Williams - Dove Analytics
DETAILS
Thursday 15th March 2018
Continuous manufacturing
Royal Society of Chemistry, London
Continuous manufacturing offers great promise in improving productivity, efficiency and the intrinsic quality of pharmaceutical products. However, despite strong regulatory support aimed at encouraging the early adoption of new technologies, which in turn would facilitate the application of modern quality management techniques to all aspects of pharmaceutical production and quality assurance; uptake by Industry has been very slow.
This symposium will critically examine some of the challenges and opportunities that arise from adopting continuous manufacturing. Leading regulators, industrialists and academics will be sharing their experiences in the development, manufacturing and quality assurance of continuous manufacturing.
Speakers:
Dr Montserrat Casadevall-Callis - GlaxoSmithKline
Dr Chris Clarke - GlaxoSmithKline
Dr Richard Hart - AstraZeneca
Prof David Littlejohn - University of Strathclyde
Petter Moree - OSIsoft
Dr Ron Ogilvie - Pfizer
Dr Colm Reddington - MHRA
Dr Patrick Wahl - RCPE
DETAILS
Continuous manufacturing
Royal Society of Chemistry, London
Continuous manufacturing offers great promise in improving productivity, efficiency and the intrinsic quality of pharmaceutical products. However, despite strong regulatory support aimed at encouraging the early adoption of new technologies, which in turn would facilitate the application of modern quality management techniques to all aspects of pharmaceutical production and quality assurance; uptake by Industry has been very slow.
This symposium will critically examine some of the challenges and opportunities that arise from adopting continuous manufacturing. Leading regulators, industrialists and academics will be sharing their experiences in the development, manufacturing and quality assurance of continuous manufacturing.
Speakers:
Dr Montserrat Casadevall-Callis - GlaxoSmithKline
Dr Chris Clarke - GlaxoSmithKline
Dr Richard Hart - AstraZeneca
Prof David Littlejohn - University of Strathclyde
Petter Moree - OSIsoft
Dr Ron Ogilvie - Pfizer
Dr Colm Reddington - MHRA
Dr Patrick Wahl - RCPE
DETAILS
Thursday 15th March 2018
Annual General Meeting
Royal Society of Chemistry, London
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 9.30 am
Click here to see the Agenda
Click here to see the Minutes of the 2017 AGM
DETAILS
Annual General Meeting
Royal Society of Chemistry, London
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 9.30 am
Click here to see the Agenda
Click here to see the Minutes of the 2017 AGM
DETAILS
Thursday 8th February 2018
Cleaning validation
Royal Society of Chemistry, London
Continuing our successful continuing programme of pharmaceutical analysis symposia, this meeting will focus on cleaning validation and is aimed at providing the latest regulatory expectations and best practice information in the domain of cleaning validation since the publication of the European Medicines Agency Shared Facilities Guideline and subsequent Q&A Document.
The meeting will explore cleaning validation requirements from a toxicologists perspective and also examine new facility design considerations to minimise the potential for cross contamination.
There will be ample opportunity to interact with the expert speakers during Q&A sessions and panel discussions throughout the day and informally during lunch and refreshment breaks.
This symposium will be of special interest to those engaged in Quality Control and Quality Assurance , Manufacturing and Validation in the Pharmaceutical and Biotech Industry, NHS manufacturing units, Contract Manufacturing Organisations, consulting, academia, and anyone else concerned with the management and assessment of cleaning validation.
Speakers:
Amir Alimohammadi - AstraZeneca
Dr Steve Alley - Reading Scientific Services Ltd
Dr Joel Bercu - Gilead
Dr Colin Gall - Fujifilm
Dr Brian Hammond - Reading Scientific Services Ltd
David Jones - Alphasonics
Beth Kroeger - Steris
Graeme McKilligan - MHRA
Dr Jon Schiotz - AstraZeneca
DETAILS
Cleaning validation
Royal Society of Chemistry, London
Continuing our successful continuing programme of pharmaceutical analysis symposia, this meeting will focus on cleaning validation and is aimed at providing the latest regulatory expectations and best practice information in the domain of cleaning validation since the publication of the European Medicines Agency Shared Facilities Guideline and subsequent Q&A Document.
The meeting will explore cleaning validation requirements from a toxicologists perspective and also examine new facility design considerations to minimise the potential for cross contamination.
There will be ample opportunity to interact with the expert speakers during Q&A sessions and panel discussions throughout the day and informally during lunch and refreshment breaks.
This symposium will be of special interest to those engaged in Quality Control and Quality Assurance , Manufacturing and Validation in the Pharmaceutical and Biotech Industry, NHS manufacturing units, Contract Manufacturing Organisations, consulting, academia, and anyone else concerned with the management and assessment of cleaning validation.
Speakers:
Amir Alimohammadi - AstraZeneca
Dr Steve Alley - Reading Scientific Services Ltd
Dr Joel Bercu - Gilead
Dr Colin Gall - Fujifilm
Dr Brian Hammond - Reading Scientific Services Ltd
David Jones - Alphasonics
Beth Kroeger - Steris
Graeme McKilligan - MHRA
Dr Jon Schiotz - AstraZeneca
DETAILS
Thursday 7th December 2017
Ensuring amorphous product quality: what are the challenges?
Royal Society of Chemistry, London
Amorphous drug formulation offers great promise in improving drug solubility - a major challenge in drug development. However, poor physical stability and hard to predict crystallisation remains key barriers for the wider use of amorphous solid solution in the pharmaceutical industry.
This symposium will critically examine the challenges and opportunities lie in the analysis of amorphous formulation systems.
Leading industrialists and academics will be sharing their experiences in the development, manufacturing and quality assurance of amorphous products.
New analytical technologies for the prediction of amorphous stability and novel PAT will be discussed.
You will gain latest knowledges on the analysis and manufacturing of amorphous/solid solution products.
You may form new collaborations with experts across academic and industry.
Speakers:
Prof Gavin Andrews - Queen's University Belfast
Prof Duncan Craig - University College London
Dr Korbinian Löbmann - University of Copenhagen
Dr Claire Pizzey - Diamond Light Source
Hans Platteeuw - Avivia
Dr Paul Royall - King's College London
Dr Abhishek Singh - Johnson & Johnson
Dr Krzysztof Sollohub - Catalent
DETAILS
Ensuring amorphous product quality: what are the challenges?
Royal Society of Chemistry, London
Amorphous drug formulation offers great promise in improving drug solubility - a major challenge in drug development. However, poor physical stability and hard to predict crystallisation remains key barriers for the wider use of amorphous solid solution in the pharmaceutical industry.
This symposium will critically examine the challenges and opportunities lie in the analysis of amorphous formulation systems.
Leading industrialists and academics will be sharing their experiences in the development, manufacturing and quality assurance of amorphous products.
New analytical technologies for the prediction of amorphous stability and novel PAT will be discussed.
You will gain latest knowledges on the analysis and manufacturing of amorphous/solid solution products.
You may form new collaborations with experts across academic and industry.
Speakers:
Prof Gavin Andrews - Queen's University Belfast
Prof Duncan Craig - University College London
Dr Korbinian Löbmann - University of Copenhagen
Dr Claire Pizzey - Diamond Light Source
Hans Platteeuw - Avivia
Dr Paul Royall - King's College London
Dr Abhishek Singh - Johnson & Johnson
Dr Krzysztof Sollohub - Catalent
DETAILS
Tuesday 28th November 2017
The pharmaceutical analysis postgraduate research awards and careers symposium
Royal Society of Chemistry, London
JPAG presents its inaugural pharmaceutical analysis symposium for postgraduate students and early career stage scientists. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through podium and poster presentations.The best podium and poster presentations will be recognised with cash prizes up to 500 GBP.
There will also be plenary lectures by leading scientists and an industrial careers exhibition:
» Professor Melissa Hanna-Brown
Prof Hanna-Brown is Technology & Innovation EU Lead, Pfizer Worldwide R&D, Sandwich, UK and Department of Chemistry, University of Warwick, UK and President of the Analytical Division, Royal Society Chemistry, UK.
» Professor Trevor Jones CBE
Prof Jones is Chairman of the international Clinical Research Organisation, Simbec-Orion, a member of the Boards of the Global Life Sciences investment company; Arix Bioscience; the Oxford based Drug Discovery Company ,e-Therapeutics; and the UK Stem Cell Foundation (UKSCF) .Formerly he was Director of Allergan Inc (USA) and R&D Director of The Wellcome Foundation.
Speakers:
Prof Melissa Hanna-Brown - Pfizer
Prof Trevor Jones - King's College London
DETAILS
The pharmaceutical analysis postgraduate research awards and careers symposium
Royal Society of Chemistry, London
JPAG presents its inaugural pharmaceutical analysis symposium for postgraduate students and early career stage scientists. This will provide the opportunity for delegates to showcase their work and network with peers, academics and industrial scientists through podium and poster presentations.The best podium and poster presentations will be recognised with cash prizes up to 500 GBP.
There will also be plenary lectures by leading scientists and an industrial careers exhibition:
» Professor Melissa Hanna-Brown
Prof Hanna-Brown is Technology & Innovation EU Lead, Pfizer Worldwide R&D, Sandwich, UK and Department of Chemistry, University of Warwick, UK and President of the Analytical Division, Royal Society Chemistry, UK.
» Professor Trevor Jones CBE
Prof Jones is Chairman of the international Clinical Research Organisation, Simbec-Orion, a member of the Boards of the Global Life Sciences investment company; Arix Bioscience; the Oxford based Drug Discovery Company ,e-Therapeutics; and the UK Stem Cell Foundation (UKSCF) .Formerly he was Director of Allergan Inc (USA) and R&D Director of The Wellcome Foundation.
Speakers:
Prof Melissa Hanna-Brown - Pfizer
Prof Trevor Jones - King's College London
DETAILS
Thursday 12th October 2017
Stability Challenges III: Assuring the stability of medicines from manufacture to use
Royal Society of Chemistry, London
Continuing our successful Stability Challenges series, this meeting is the third in the series and is aimed at providing the latest information and best practice on many aspects of stability testing. In this particular meeting the focus will be on data evaluation, discussing the estimation and prediction of shelf lives, including physical stability, and the effects of temperature and humidity excursions. Also the efficient application of stability testing according to lean laboratory principles will be explored along with MHRA views on stability requirements and GMDP expectations.
The focus of this meeting is to examine best practice during the distribution and storage of medicines, to ensure correct storage conditions are maintained and to ensure the quality of the medicine is maintained during use in the clinic or by the patient. The generation of data to support temperature excursions and to demonstrate in-use stability will be explored.
This symposium will be of special interest to those engaged in Quality Control and Quality Assurance, pharmaceutical development, regulatory affairs, storage and distribution in the Pharmaceutical Industry, NHS manufacturing units, Contract Research Organisations, consulting, academia, and anyone else concerned with the management and assessment of drug stability.
Speakers:
Dr Paul Whiteside - Pfizer
Miles Ambler - GlaxoSmithKline
Francisco de Matos Afonso Pereira - MHRA
Dr Niels Hartvig - Novo Nordisk
Dr Samuel Kyeremateng - Abbvie
Dr Kristin Lehmkemper - Abbvie
Dr Peter O'Connell - Cuspor
Dr Klimentina Pencheva - Pfizer
Dr Garry Scrivens - Pfizer
DETAILS
Stability Challenges III: Assuring the stability of medicines from manufacture to use
Royal Society of Chemistry, London
Continuing our successful Stability Challenges series, this meeting is the third in the series and is aimed at providing the latest information and best practice on many aspects of stability testing. In this particular meeting the focus will be on data evaluation, discussing the estimation and prediction of shelf lives, including physical stability, and the effects of temperature and humidity excursions. Also the efficient application of stability testing according to lean laboratory principles will be explored along with MHRA views on stability requirements and GMDP expectations.
The focus of this meeting is to examine best practice during the distribution and storage of medicines, to ensure correct storage conditions are maintained and to ensure the quality of the medicine is maintained during use in the clinic or by the patient. The generation of data to support temperature excursions and to demonstrate in-use stability will be explored.
This symposium will be of special interest to those engaged in Quality Control and Quality Assurance, pharmaceutical development, regulatory affairs, storage and distribution in the Pharmaceutical Industry, NHS manufacturing units, Contract Research Organisations, consulting, academia, and anyone else concerned with the management and assessment of drug stability.
Speakers:
Dr Paul Whiteside - Pfizer
Miles Ambler - GlaxoSmithKline
Francisco de Matos Afonso Pereira - MHRA
Dr Niels Hartvig - Novo Nordisk
Dr Samuel Kyeremateng - Abbvie
Dr Kristin Lehmkemper - Abbvie
Dr Peter O'Connell - Cuspor
Dr Klimentina Pencheva - Pfizer
Dr Garry Scrivens - Pfizer
DETAILS
Thursday 22nd June 2017
Counterfeit medicines
Royal Society of Chemistry, London
It is now widely accepted that counterfeiting is a huge and growing challenge of global proportion.
This symposium will take an overview of the problems authenticity must address from three different perspectives:
• The problem Globally
• The critical role of Discovery and Compliance
• The key role that authentic APIs play in Risk Management
each of which will be supported by relevant case studies.
Speakers:
Andrew Davies - NHS Improvement
Michael Deats - W.H.O.
Adam Harris - Quintiles IMS
Prof Trevor Jones - King's College London
Kyle Leeman - Pfizer
Kenneth Leiper - Benson Associates
Dr Per Troein - Quintiles IMS
Dr Steve Wicks - Medway Centre for Pharmaceutical Sciences
DETAILS
Counterfeit medicines
Royal Society of Chemistry, London
It is now widely accepted that counterfeiting is a huge and growing challenge of global proportion.
This symposium will take an overview of the problems authenticity must address from three different perspectives:
• The problem Globally
• The critical role of Discovery and Compliance
• The key role that authentic APIs play in Risk Management
each of which will be supported by relevant case studies.
Speakers:
Andrew Davies - NHS Improvement
Michael Deats - W.H.O.
Adam Harris - Quintiles IMS
Prof Trevor Jones - King's College London
Kyle Leeman - Pfizer
Kenneth Leiper - Benson Associates
Dr Per Troein - Quintiles IMS
Dr Steve Wicks - Medway Centre for Pharmaceutical Sciences
DETAILS
Thursday 11th May 2017
The role of MS in impurity profiling
Royal Society of Chemistry, London
In association with the British Mass Spectrometry Society.
Impurities provide no benefit to patients; however, it is pragmatically accepted that complex, multi-stage pharmaceuticals cannot be manufactured without drug substance impurities or that drug products cannot be manufactured and stored without degradation products.
This symposium will explore the role of Mass Spectrometry (MS) in the identification and quantification of the various impurities that can be formed.
This symposium should be of interest to development, production, and academic scientists, as well as contract research organisations (CROs).
Speakers:
Dr Claudio Brunelli - Pfizer
Dr Elspeth Gray - MHRA
Dr Sarah James - LGC
Dr Martin Ott - Lhasa
Dr Mark Perkins - Anatune
Dr Andrew Ray - AstraZeneca
Dr Mansoor Saeed - Syngenta
Alec Simpson - GlaxoSmithKline
DETAILS
The role of MS in impurity profiling
Royal Society of Chemistry, London
In association with the British Mass Spectrometry Society.
Impurities provide no benefit to patients; however, it is pragmatically accepted that complex, multi-stage pharmaceuticals cannot be manufactured without drug substance impurities or that drug products cannot be manufactured and stored without degradation products.
This symposium will explore the role of Mass Spectrometry (MS) in the identification and quantification of the various impurities that can be formed.
This symposium should be of interest to development, production, and academic scientists, as well as contract research organisations (CROs).
Speakers:
Dr Claudio Brunelli - Pfizer
Dr Elspeth Gray - MHRA
Dr Sarah James - LGC
Dr Martin Ott - Lhasa
Dr Mark Perkins - Anatune
Dr Andrew Ray - AstraZeneca
Dr Mansoor Saeed - Syngenta
Alec Simpson - GlaxoSmithKline
DETAILS
Thursday 16th March 2017
Assuring data integrity; best practice
Royal Society of Chemistry, London
Data integrity is receiving much attention in the pharmaceutical industry, with several high profile cases where deficiencies have resulted in regulatory action, and the MHRA, FDA, EMA and WHO have all issued guidance documents recently.
This symposium will bring together experts from Health Authorities, pharmaceutical companies, CROs and technology -providers to discuss the approaches being taken to rise to the challenge of increased scrutiny of data management practices.
Speakers:
Steven Brown - Novartis
Dr Adrian Davis - Pfizer Worldwide R&D
Dean Harris - Envigo Ltd
Tracy Moore - MHRA
Dr Gerhard Noelken - Data4Lab Ltd
Paul Smith - Agilent
Mark Stevens - Formpipe Life Science
DETAILS
Assuring data integrity; best practice
Royal Society of Chemistry, London
Data integrity is receiving much attention in the pharmaceutical industry, with several high profile cases where deficiencies have resulted in regulatory action, and the MHRA, FDA, EMA and WHO have all issued guidance documents recently.
This symposium will bring together experts from Health Authorities, pharmaceutical companies, CROs and technology -providers to discuss the approaches being taken to rise to the challenge of increased scrutiny of data management practices.
Speakers:
Steven Brown - Novartis
Dr Adrian Davis - Pfizer Worldwide R&D
Dean Harris - Envigo Ltd
Tracy Moore - MHRA
Dr Gerhard Noelken - Data4Lab Ltd
Paul Smith - Agilent
Mark Stevens - Formpipe Life Science
DETAILS
Thursday 16th March 2017
Annual General Meeting
Royal Society of Chemistry, London
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 9.30 am
Click here to see the Notice
Click here to see the Minutes of the 2016 AGM
DETAILS
Annual General Meeting
Royal Society of Chemistry, London
This is a closed meeting for members of JPAG
It is not necessary to register for the symposium to attend the AGM
Starts at 9.30 am
Click here to see the Notice
Click here to see the Minutes of the 2016 AGM
DETAILS
Thursday 9th February 2017
Dissolution testing: current and future considerations
Royal Society of Chemistry, London
Dissolution and disintegration tests for solid oral dosage forms provide insight into the rate of release of the drug into the body. Dissolution has been viewed solely as a quality control tool, but more recently this view has started to change and now there is clear expectation that dissolution must have clinical relevance.
However, the challenge remains: how can a single test be sensitive enough to predict changes that may be of clinical relevance, whilst being robust enough to satisfy the needs of a quality control environment?
This symposium will explore the current state of these techniques from a regulatory, pharmacopoeia, academic and industry perspective, and how emerging bio-relevant dissolution tools can improve our prediction of oral drug behaviour.
This symposium should be attractive to scientists working in research & development, quality control, regulatory, pharmacopoeias and academia. In addition senior managers will benefit from attending.
This symposium is organised in association with the OrBiTo consortium.
Speakers:
jazz22@cam.ac.uk -
Dr Karin Boon - MHRA
Dr Karl Box - Sirius Analytical
Dr James Butler - GlaxoSmithKline
Dr David Elder - JPAG/Consultant
Dr Edmund Kostewicz - Frankfurt University
Dr James Mann - AstraZeneca
Steve Young - MHRA
DETAILS
Dissolution testing: current and future considerations
Royal Society of Chemistry, London
Dissolution and disintegration tests for solid oral dosage forms provide insight into the rate of release of the drug into the body. Dissolution has been viewed solely as a quality control tool, but more recently this view has started to change and now there is clear expectation that dissolution must have clinical relevance.
However, the challenge remains: how can a single test be sensitive enough to predict changes that may be of clinical relevance, whilst being robust enough to satisfy the needs of a quality control environment?
This symposium will explore the current state of these techniques from a regulatory, pharmacopoeia, academic and industry perspective, and how emerging bio-relevant dissolution tools can improve our prediction of oral drug behaviour.
This symposium should be attractive to scientists working in research & development, quality control, regulatory, pharmacopoeias and academia. In addition senior managers will benefit from attending.
This symposium is organised in association with the OrBiTo consortium.
Speakers:
jazz22@cam.ac.uk -
Dr Karin Boon - MHRA
Dr Karl Box - Sirius Analytical
Dr James Butler - GlaxoSmithKline
Dr David Elder - JPAG/Consultant
Dr Edmund Kostewicz - Frankfurt University
Dr James Mann - AstraZeneca
Steve Young - MHRA
DETAILS
Thursday 1st December 2016
Regulatory Hot Topics II
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with the implementation of new and emerging guidelines.
It will provide the opportunity for dialogue and discussion through an effective forum to understand, interpret and translate into day-to-day practice on topics including: ICH Q3D; ICH Q12; continuous manufacture; excipient GMP; allowable flexibility in analytical methods; development and filing of a breakthrough status medicine; microbiological quality of non-sterile dosage forms (USP 1111 and 1115)
Speakers:
Dr Gurjit Bajwa - GlaxoSmithKline
Paul Butterworth - AstraZeneca
Dr Graham Cook - Pfizer
Dr David Elder - JPAG/Consultant
Ewan Norton - MHRA
Dr Stephen Smith - AstraZeneca
Dr Andrew Teasdale - AstraZeneca
DETAILS
Regulatory Hot Topics II
Royal Society of Chemistry, London
This one-day symposium will address issues and challenges associated with the implementation of new and emerging guidelines.
It will provide the opportunity for dialogue and discussion through an effective forum to understand, interpret and translate into day-to-day practice on topics including: ICH Q3D; ICH Q12; continuous manufacture; excipient GMP; allowable flexibility in analytical methods; development and filing of a breakthrough status medicine; microbiological quality of non-sterile dosage forms (USP 1111 and 1115)
Speakers:
Dr Gurjit Bajwa - GlaxoSmithKline
Paul Butterworth - AstraZeneca
Dr Graham Cook - Pfizer
Dr David Elder - JPAG/Consultant
Ewan Norton - MHRA
Dr Stephen Smith - AstraZeneca
Dr Andrew Teasdale - AstraZeneca
DETAILS
Thursday 13th October 2016
Good Distribution Practice: solving implementation and quality issues
Royal Society of Chemistry, London
In a globalised healthcare ecosystem, supply chains become more complex, with an increased potential for quality issue to arises. So, it is critically important to understand Good Distribution Practices (GDP) and the requirements for shared responsibilities throughout the entire supply chain.
This symposium will examine the regulatory requirements of GDP, provide an understanding of the issues and demonstrate how common problem can be overcome.
Speakers:
Julia Claus - Pfizer
Afshin Hosseiny - Tabriz Consulting
Christopher Jones - AstraZeneca
Philip Neale - MHRA
Paul O'Connor - Almac Group
Fiona Routley - AstraZeneca
Emma Thomson - Mawdsleys Clinical Services
Dr Manuel Zahn - 3R Pharma Consulting GmbH
DETAILS
Good Distribution Practice: solving implementation and quality issues
Royal Society of Chemistry, London
In a globalised healthcare ecosystem, supply chains become more complex, with an increased potential for quality issue to arises. So, it is critically important to understand Good Distribution Practices (GDP) and the requirements for shared responsibilities throughout the entire supply chain.
This symposium will examine the regulatory requirements of GDP, provide an understanding of the issues and demonstrate how common problem can be overcome.
Speakers:
Julia Claus - Pfizer
Afshin Hosseiny - Tabriz Consulting
Christopher Jones - AstraZeneca
Philip Neale - MHRA
Paul O'Connor - Almac Group
Fiona Routley - AstraZeneca
Emma Thomson - Mawdsleys Clinical Services
Dr Manuel Zahn - 3R Pharma Consulting GmbH
DETAILS
Thursday 23rd June 2016
Practical implementation of ICH Q3D; challenges and solutions
Royal Society of Chemistry, London
This symposium will critically examine the practical challenges associated with effective implementation of ICH Q3D
Speakers:
Dr John Kauffman, FDA
Sven-Erik Hillver, Swedish MPA
Dr Andrew Teasdale, AstraZeneca
Dr Laurence Harris, Pfizer
Samuel Powell, Pfizer
Rob Sharp, GSK
Kevin Hughes, Colorcon
DETAILS
Practical implementation of ICH Q3D; challenges and solutions
Royal Society of Chemistry, London
This symposium will critically examine the practical challenges associated with effective implementation of ICH Q3D
Speakers:
Dr John Kauffman, FDA
Sven-Erik Hillver, Swedish MPA
Dr Andrew Teasdale, AstraZeneca
Dr Laurence Harris, Pfizer
Samuel Powell, Pfizer
Rob Sharp, GSK
Kevin Hughes, Colorcon
DETAILS
Thursday 12th May 2016
Sterility assurance best practice for aseptically manufactured products
Royal Society of Chemistry, London
The purpose of the meeting is to deliver a best practice forum of like-minded professionals engaged in the manufacture of aseptic pharmaceutical products. JPAG have assembled a strong line up of opinion leaders and experts from the UK regulator, the MHRA, industry and the NHS in the field of aseptic manufacture and microbiological monitoring and testing to provide an excellent opportunity for networking and bench marking for delegates.
The meeting will also play host to equipment providers to show the current state of the art in aseptic manufacturing and testing equipment.
Speakers:
James Drinkwater - Pharmaceutical and Healthcare Sciences Society
Dawn Hiles - Newcastle Cellular Therapies Facility, International Centre for Life
Andrew Hopkins - Expert GMDP Inspector, MHRA
Dr Aileen Hume - AMRI
Yan Hunter-Blair - Newcastle upon Tyne NHS Foundation Trust
Dr Paul Newby - GlaxoSmithKline
Dr Tim Sandle - Pharmaceutical Microbiology Interest Group (Pharmig)
DETAILS
Sterility assurance best practice for aseptically manufactured products
Royal Society of Chemistry, London
The purpose of the meeting is to deliver a best practice forum of like-minded professionals engaged in the manufacture of aseptic pharmaceutical products. JPAG have assembled a strong line up of opinion leaders and experts from the UK regulator, the MHRA, industry and the NHS in the field of aseptic manufacture and microbiological monitoring and testing to provide an excellent opportunity for networking and bench marking for delegates.
The meeting will also play host to equipment providers to show the current state of the art in aseptic manufacturing and testing equipment.
Speakers:
James Drinkwater - Pharmaceutical and Healthcare Sciences Society
Dawn Hiles - Newcastle Cellular Therapies Facility, International Centre for Life
Andrew Hopkins - Expert GMDP Inspector, MHRA
Dr Aileen Hume - AMRI
Yan Hunter-Blair - Newcastle upon Tyne NHS Foundation Trust
Dr Paul Newby - GlaxoSmithKline
Dr Tim Sandle - Pharmaceutical Microbiology Interest Group (Pharmig)
DETAILS
Thursday 17th March 2016
The use of in silico modelling in drug development
Royal Society of Chemistry, London
This symposium is held in association with the Academy of Pharmaceutical Sciences (APS)
This major symposium will provide essential information for all those involved in:
• Formulating medicinal products
• Developing manufacturing processes
• Problem solving and root cause analysis
• Quality control
This symposium is held in association with the Academy of Pharmaceutical Sciences (APS)
Speakers:
Susan Cole - MHRA
Dr Darren Green - GlaxoSmithKline
Dr David Palmer - University of Strathclyde
Dr Kendal Pitt - GlaxoSmithKline
Dr Andrew Teasdale - AstraZeneca
Dr Helen Williams - AstraZeneca
Dr Richard Williams - Lhasa
DETAILS
The use of in silico modelling in drug development
Royal Society of Chemistry, London
This symposium is held in association with the Academy of Pharmaceutical Sciences (APS)
This major symposium will provide essential information for all those involved in:
• Formulating medicinal products
• Developing manufacturing processes
• Problem solving and root cause analysis
• Quality control
This symposium is held in association with the Academy of Pharmaceutical Sciences (APS)
Speakers:
Susan Cole - MHRA
Dr Darren Green - GlaxoSmithKline
Dr David Palmer - University of Strathclyde
Dr Kendal Pitt - GlaxoSmithKline
Dr Andrew Teasdale - AstraZeneca
Dr Helen Williams - AstraZeneca
Dr Richard Williams - Lhasa
DETAILS
Thursday 17th March 2016
JPAG Annual General Meeting
Royal Society of Chemistry, London. Science Room
Starts at 9.30 a.m.
The AGM is open to all members of JPAG. It is not necessary to register for the symposium to attend the AGM.
DETAILS
JPAG Annual General Meeting
Royal Society of Chemistry, London. Science Room
Starts at 9.30 a.m.
The AGM is open to all members of JPAG. It is not necessary to register for the symposium to attend the AGM.
DETAILS
Thursday 4th February 2016
Solving problems with spectral imaging
Royal Society of Chemistry, London
This symposium is held jointly with the Academy of Pharmaceutical Sciences (APS)
Hyperspectral spectral imaging brings great advantages to pharmaceutical analysis by combining the best in spectroscopy and imaging. It solves many problems in analysing solid dosage forms: particle size, shape and distribution; moisture content and location, identification and quantification of individual constituents including polymorphic forms; content uniformity; and assessment of homogeneity
Speakers:
Johannes Khinast - Graz University of Technology
Stephanie Brookes - AstraZeneca
Gerard Byrne - Merck
Sergei Kazarian - Imperial College London
Martin Kuentz - Basel University
Daniel Markl - Graz University of Technology
Christina Pattoni - Pfizer
Dr Sheng Qi - University of East Anglia
DETAILS
Solving problems with spectral imaging
Royal Society of Chemistry, London
This symposium is held jointly with the Academy of Pharmaceutical Sciences (APS)
Hyperspectral spectral imaging brings great advantages to pharmaceutical analysis by combining the best in spectroscopy and imaging. It solves many problems in analysing solid dosage forms: particle size, shape and distribution; moisture content and location, identification and quantification of individual constituents including polymorphic forms; content uniformity; and assessment of homogeneity
Speakers:
Johannes Khinast - Graz University of Technology
Stephanie Brookes - AstraZeneca
Gerard Byrne - Merck
Sergei Kazarian - Imperial College London
Martin Kuentz - Basel University
Daniel Markl - Graz University of Technology
Christina Pattoni - Pfizer
Dr Sheng Qi - University of East Anglia
DETAILS
Thursday 10th December 2015
Maximising productivity in pharmaceutical QC and stability testing
Royal Society of Chemistry, London
The pressure to increase productivity in the pharmaceutical industry, whilst maintaining compliance and reducing costs, is relentless. This meeting will examine the role of technologies and continuous improvement techniques in optimising throughput, cycle times and allocation of resources in QC and stability testing laboratories, using expert perspectives and case studies from industry, regulatory agencies and partner organisations.
Speakers:
Joanne Hay - MSD
Lesley Graham - MHRA
Andy Rice - GlaxoSmithKline
Susan Smith - AstraZeneca
Roman Szucs - Pfizer
John Trigg - Phasefour-informatics
Bill Young - GlaxoSmithKline
DETAILS
Maximising productivity in pharmaceutical QC and stability testing
Royal Society of Chemistry, London
The pressure to increase productivity in the pharmaceutical industry, whilst maintaining compliance and reducing costs, is relentless. This meeting will examine the role of technologies and continuous improvement techniques in optimising throughput, cycle times and allocation of resources in QC and stability testing laboratories, using expert perspectives and case studies from industry, regulatory agencies and partner organisations.
Speakers:
Joanne Hay - MSD
Lesley Graham - MHRA
Andy Rice - GlaxoSmithKline
Susan Smith - AstraZeneca
Roman Szucs - Pfizer
John Trigg - Phasefour-informatics
Bill Young - GlaxoSmithKline
DETAILS
Thursday 8th October 2015
What's new in the approval and conduct of clinical trials in Europe?
Royal Society of Chemistry, London
The implementation of the EU Clinical Trials Directive in May 2004 resulted in significant changes in the approval process and conduct of clinical trials in the EU.
This symposium will describe the changes that are to be introduced by the Regulation, how and when these changes will be implemented, and how this is likely to impact on the attractiveness of the EU for conducting clinical research.
Speakers:
Anne Black - Newcastle upon Tyne Hospital
Dr Graham McNaughton - MHRA
Dr Martin O'Kane - MHRA
Michelle Rowson - MHRA
Dr Peter Scholes - Quotient Clinical
Dave White - AstraZeneca
DETAILS
What's new in the approval and conduct of clinical trials in Europe?
Royal Society of Chemistry, London
The implementation of the EU Clinical Trials Directive in May 2004 resulted in significant changes in the approval process and conduct of clinical trials in the EU.
This symposium will describe the changes that are to be introduced by the Regulation, how and when these changes will be implemented, and how this is likely to impact on the attractiveness of the EU for conducting clinical research.
Speakers:
Anne Black - Newcastle upon Tyne Hospital
Dr Graham McNaughton - MHRA
Dr Martin O'Kane - MHRA
Michelle Rowson - MHRA
Dr Peter Scholes - Quotient Clinical
Dave White - AstraZeneca
DETAILS
Thursday 25th June 2015
Challenges in current GMP
Royal Society of Chemistry, London
This programme will focus on current key aspects of GMP, including the evolution of cGMPs since the publication of ICH Q7 in 2000, the potential impact of the ICH Implementation Group and their development of Q&As relating to ICH Q7, and the implications of the EMA Guidelines on shared facilities and exposure limits.
DETAILS
Challenges in current GMP
Royal Society of Chemistry, London
This programme will focus on current key aspects of GMP, including the evolution of cGMPs since the publication of ICH Q7 in 2000, the potential impact of the ICH Implementation Group and their development of Q&As relating to ICH Q7, and the implications of the EMA Guidelines on shared facilities and exposure limits.
DETAILS
Thursday 14th May 2015
Antibody drug conjugates: analytical efforts and expectations
Royal Society of Chemistry, London
Antibody drug conjugates (ADCs) are an exciting and challenging new area of research and are becoming ever more popular across the industry with more than 50 ADCs reported in the clinic. The targeted nature of the molecules makes them extremely suitable for delivering toxic molecules to the target.
Members of the Drug Metabolism Discussion Group can register at the members rate.
DETAILS
Antibody drug conjugates: analytical efforts and expectations
Royal Society of Chemistry, London
Antibody drug conjugates (ADCs) are an exciting and challenging new area of research and are becoming ever more popular across the industry with more than 50 ADCs reported in the clinic. The targeted nature of the molecules makes them extremely suitable for delivering toxic molecules to the target.
Members of the Drug Metabolism Discussion Group can register at the members rate.
DETAILS
Thursday 19th March 2015
Combating counterfeit medicines: the solutions
Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA
Sub-standard and counterfeit medicines are a great threat to patient health and safety. They may cause death due to the lack of active drug, as found in some vaccines and antibiotics, or because of the presence of a toxic material, such as the substitution of diethylene glycol for glycerol.
DETAILS
Combating counterfeit medicines: the solutions
Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA
Sub-standard and counterfeit medicines are a great threat to patient health and safety. They may cause death due to the lack of active drug, as found in some vaccines and antibiotics, or because of the presence of a toxic material, such as the substitution of diethylene glycol for glycerol.
DETAILS
Thursday 19th March 2015
Annual General Meeting
Royal Society of Chemistry, London
Starts at 9.30 a.m.
The AGM is open to all members of JPAG. It is not necessary to register for the symposium to attend the AGM.
Annual General Meeting
Royal Society of Chemistry, London
Starts at 9.30 a.m.
The AGM is open to all members of JPAG. It is not necessary to register for the symposium to attend the AGM.
Thursday 5th February 2015
Quality Risk Management: a pragmatic approach
GlaxoSmithKline, Ware
An effective quality risk management (QRM) process provides a key mechanism for the proactive identification and control of potential issues that may arise during product development and subsequent commercialisation (ICH Q9).
Scientific approaches are used to estimate the likelihood of any given risk.
This symposium will look at the assessment of risk from an academic, regulatory and industrial perspective and will cover method development, specification setting, chemical purging and genotoxin risk assessment (GRA) using in silico methodologies.
DETAILS
Quality Risk Management: a pragmatic approach
GlaxoSmithKline, Ware
An effective quality risk management (QRM) process provides a key mechanism for the proactive identification and control of potential issues that may arise during product development and subsequent commercialisation (ICH Q9).
Scientific approaches are used to estimate the likelihood of any given risk.
This symposium will look at the assessment of risk from an academic, regulatory and industrial perspective and will cover method development, specification setting, chemical purging and genotoxin risk assessment (GRA) using in silico methodologies.
DETAILS
Thursday 11th December 2014
Stability challenges Part II: Assuring the stability of medicines from manufacture to clinical use
Royal Society of Chemistry, London
This symposium examines best practice during the distribution and storage of medicines, to ensure correct storage conditions are maintained and to ensure the quality of the medicine is maintained during use in the clinic or by the patient. The generation of data to support temperature excursions and to demonstrate in-use stability will be explored.
DETAILS
Stability challenges Part II: Assuring the stability of medicines from manufacture to clinical use
Royal Society of Chemistry, London
This symposium examines best practice during the distribution and storage of medicines, to ensure correct storage conditions are maintained and to ensure the quality of the medicine is maintained during use in the clinic or by the patient. The generation of data to support temperature excursions and to demonstrate in-use stability will be explored.
DETAILS
Thursday 3rd July 2014
Assuring the quality of medicines
Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA
The quality of the drug substance and the drug product is critical to ensure the safety and efficacy of medicines. If you have any role in ensuring the quality of medicines, do you have all the tools you need to resolve every-day quality issues?
Qualified Persons (QPs) have a critical role in releasing batches of pharmaceutical products. An understanding of the supply chain and manufacturing challenges is an essential component to the conduct of this role. This symposium takes a strategic look at solving everyday quality issues and the changing role of QPs.
DETAILS
Assuring the quality of medicines
Royal Society of Chemistry, Burlington House, Piccadilly, London W1J 0BA
The quality of the drug substance and the drug product is critical to ensure the safety and efficacy of medicines. If you have any role in ensuring the quality of medicines, do you have all the tools you need to resolve every-day quality issues?
Qualified Persons (QPs) have a critical role in releasing batches of pharmaceutical products. An understanding of the supply chain and manufacturing challenges is an essential component to the conduct of this role. This symposium takes a strategic look at solving everyday quality issues and the changing role of QPs.
DETAILS
Thursday 15th May 2014
Combating counterfeit medicines: a major and growing challenge to patient safety. Going global
Royal Society of Chemistry, London
Counterfeit medicines - or more appropriately - fake medicines pose great dangers to society. Regrettably, fake medicines are not a new phenomenon. What is new, however, is the recent global escalation of both counterfeit prescriptions and consumer healthcare products.
This symposium provides a current and strategic overview of how industry and regulatory authorities in Europe and the US are addressing the rapidly growing counterfeiting challenge.
This symposium is run in partnership with the Royal Pharmaceutical Society. Members of the Royal Pharmaceutical Society can register at the Members Rate.
DETAILS
Combating counterfeit medicines: a major and growing challenge to patient safety. Going global
Royal Society of Chemistry, London
Counterfeit medicines - or more appropriately - fake medicines pose great dangers to society. Regrettably, fake medicines are not a new phenomenon. What is new, however, is the recent global escalation of both counterfeit prescriptions and consumer healthcare products.
This symposium provides a current and strategic overview of how industry and regulatory authorities in Europe and the US are addressing the rapidly growing counterfeiting challenge.
This symposium is run in partnership with the Royal Pharmaceutical Society. Members of the Royal Pharmaceutical Society can register at the Members Rate.
DETAILS
Thursday 20th March 2014
Pharmaceutical equivalence, therapeutic equivalence and the role of analytical science
Royal Society of Chemistry, London
The assumption that pharmaceutical equivalence predicts therapeutic equivalence is becoming increasingly contested. The greater complexity of medicinal products and their global sourcing .challenge this belief. Have you been following this important discussion? Do you know and understand what important developments in the scientific and regulatory frameworks are taking place? Are you aware of the implications for the safe use of medicines?
Members of TOPRA can register at the members rate for this event
DETAILS
Pharmaceutical equivalence, therapeutic equivalence and the role of analytical science
Royal Society of Chemistry, London
The assumption that pharmaceutical equivalence predicts therapeutic equivalence is becoming increasingly contested. The greater complexity of medicinal products and their global sourcing .challenge this belief. Have you been following this important discussion? Do you know and understand what important developments in the scientific and regulatory frameworks are taking place? Are you aware of the implications for the safe use of medicines?
Members of TOPRA can register at the members rate for this event
DETAILS
Thursday 20th March 2014
Annual General Meeting of JPAG
Royal Society of Chemistry, London
The 44th Annual General Meeting of the Group will be held before the Group symposium and will commence at 9.30 a.m.
Please note that you are able to attend the AGM (only) without registering for the symposium.
This meeting is open to members of JPAG only.
DETAILS
Annual General Meeting of JPAG
Royal Society of Chemistry, London
The 44th Annual General Meeting of the Group will be held before the Group symposium and will commence at 9.30 a.m.
Please note that you are able to attend the AGM (only) without registering for the symposium.
This meeting is open to members of JPAG only.
DETAILS
Thursday 6th February 2014
Developments in analysis of orally inhaled and nasal drug products
Royal Society of Chemistry, London
This symposium will provide delegates working in the analysis, development or regulation of orally inhaled and nasal drug products with an update on recent developments in the field.
DETAILS
Developments in analysis of orally inhaled and nasal drug products
Royal Society of Chemistry, London
This symposium will provide delegates working in the analysis, development or regulation of orally inhaled and nasal drug products with an update on recent developments in the field.
DETAILS
Wednesday 11th December 2013
Dissolution of inhaled products: in vitro developments, in vivo relevance and the potential impact on regulatory thinking
Edinburgh International Conference Centre
JPAG half-day symposium in association with the Drug Delivery to the Lungs 24 annual conference organised by The Aerosol Society.
The panel of speakers;: Sau Lee, U.S FDA; Sabine May, PharmBioTec, Sarbrucken, Germany; Rob Price, University of Bath; and Robyn Sadler, GSK
DETAILS
Dissolution of inhaled products: in vitro developments, in vivo relevance and the potential impact on regulatory thinking
Edinburgh International Conference Centre
JPAG half-day symposium in association with the Drug Delivery to the Lungs 24 annual conference organised by The Aerosol Society.
The panel of speakers;: Sau Lee, U.S FDA; Sabine May, PharmBioTec, Sarbrucken, Germany; Rob Price, University of Bath; and Robyn Sadler, GSK
DETAILS
Thursday 10th October 2013
ICH Q3D (Metals Guidelines): Opportunities and challenges
Royal Society of Chemistry, London
New regulations are coming! So, what do you know about ICH Q3D, and what you require to do to ensure you have appropriate control over metals in your products?
Are you confused about why the USP is implementing new general chapters on metals (<232> and <233>) next year that are not fully aligned with either Ph. Eur., or (potentially) Q3D? Are you concerned about your lack of awareness of ICH Q3D?
What do the other pharmacopoeias plan to do? What are the regulators views? What are industry’s views?
This symposium will provide you with the opportunity to network with experts, and fellow workers trying to assess the complexity and resource burden that this guidance may bring.
DETAILS
ICH Q3D (Metals Guidelines): Opportunities and challenges
Royal Society of Chemistry, London
New regulations are coming! So, what do you know about ICH Q3D, and what you require to do to ensure you have appropriate control over metals in your products?
Are you confused about why the USP is implementing new general chapters on metals (<232> and <233>) next year that are not fully aligned with either Ph. Eur., or (potentially) Q3D? Are you concerned about your lack of awareness of ICH Q3D?
What do the other pharmacopoeias plan to do? What are the regulators views? What are industry’s views?
This symposium will provide you with the opportunity to network with experts, and fellow workers trying to assess the complexity and resource burden that this guidance may bring.
DETAILS
Thursday 4th July 2013
Meeting stability challenges
Royal Society of Chemistry, London
Are you are involved in any aspects of design, implementation or interpretation of stability studies? If so, this one-day symposium will bring you up to speed with current best practice, with presentations from experts in the regulatory and industrial environment, to help you to meet the challenges of your work.
DETAILS
Meeting stability challenges
Royal Society of Chemistry, London
Are you are involved in any aspects of design, implementation or interpretation of stability studies? If so, this one-day symposium will bring you up to speed with current best practice, with presentations from experts in the regulatory and industrial environment, to help you to meet the challenges of your work.
DETAILS
Thursday 16th May 2013
New approaches in bioanalysis and analytical toxicology
Royal Society of Chemistry, London
Increasingly asked to provide ever-more analytical data?
Are the samples becoming smaller, more complex and more challenging to deal with?
Our experts will reveal their novel solutions to answer these challenges with radical new approaches to make the impossible possible.
Held in partnership with the Drug Metabolism Discussion Group.
DETAILS
New approaches in bioanalysis and analytical toxicology
Royal Society of Chemistry, London
Increasingly asked to provide ever-more analytical data?
Are the samples becoming smaller, more complex and more challenging to deal with?
Our experts will reveal their novel solutions to answer these challenges with radical new approaches to make the impossible possible.
Held in partnership with the Drug Metabolism Discussion Group.
DETAILS
Thursday 21st March 2013
Progress and challenges in pharmaceutical harmonisation
Royal Society of Chemistry, London
Aware of the latest harmonised CMC guidelines? Not sure how to implement them successfully?
From control of impurities to Quality by Design, let our expert speakers update you on the latest CMC developments and issues for international registration.
Come and share your questions and experiences with our speaker panel and fellow pharmaceutical professionals in this great networking opportunity.
If you develop or register new chemical entities, register now - places are limited.
DETAILS
Progress and challenges in pharmaceutical harmonisation
Royal Society of Chemistry, London
Aware of the latest harmonised CMC guidelines? Not sure how to implement them successfully?
From control of impurities to Quality by Design, let our expert speakers update you on the latest CMC developments and issues for international registration.
Come and share your questions and experiences with our speaker panel and fellow pharmaceutical professionals in this great networking opportunity.
If you develop or register new chemical entities, register now - places are limited.
DETAILS
Thursday 21st March 2013
Annual General Meeting of JPAG
Royal Society of Chemistry, London
The 43rd Annual General Meeting of the Group will be held before the Group symposium and will commence at 9.30 a.m.
Please note that you are able to attend the AGM (only) without registering for the symposium.
DETAILS
Annual General Meeting of JPAG
Royal Society of Chemistry, London
The 43rd Annual General Meeting of the Group will be held before the Group symposium and will commence at 9.30 a.m.
Please note that you are able to attend the AGM (only) without registering for the symposium.
DETAILS
Thursday 7th February 2013
Assuring the quality of medicines
Royal Society of Chemistry, London
Do you deal with issues on the quality of medicines?
If so, you will want to attend this major symposium which takes a strategic look at resolving day-to-day issues on the quality of medicines.
The programme addresses the role of human error and how to minimise its effects, the security of the supply chain for APIs, the changing role of Qualified Persons and others working in quality control, and the MHRA Surveillance Programme.
Completing a line-up of experts from industry and the regulatory agency will be a panel from the FDA who will examine the transition from validation of batches to the verification of continuous processes.
If you are a QP, or your work relates to any aspect of medicine quality, this is a "must-attend" event.
DETAILS
Assuring the quality of medicines
Royal Society of Chemistry, London
Do you deal with issues on the quality of medicines?
If so, you will want to attend this major symposium which takes a strategic look at resolving day-to-day issues on the quality of medicines.
The programme addresses the role of human error and how to minimise its effects, the security of the supply chain for APIs, the changing role of Qualified Persons and others working in quality control, and the MHRA Surveillance Programme.
Completing a line-up of experts from industry and the regulatory agency will be a panel from the FDA who will examine the transition from validation of batches to the verification of continuous processes.
If you are a QP, or your work relates to any aspect of medicine quality, this is a "must-attend" event.
DETAILS
Thursday 17th May 2012
Advances in Raman spectroscopy in pharmaceutical analysis
Royal Society of Chemistry, London
This major symposium was oganised jointly by the Federation of Analytical Chemistry and Spectroscopy Societies (FACSS), the Joint Pharmaceutical Analysis Group (JPAG), the Royal Society of Chemistry Molecular Spectroscopy Group (MSG) and the Infrared & Raman Discussion Group (IRDG)
Raman spectroscopy has found favour in pharmaceutical analysis because it is non-destructive, requires minimal sample preparation and gives clear spectra for identification. The programme demonstrated a breadth of successful Raman applications spanning the R&D field, active pharmaceutical ingredients (API) development, scale-up and manufacturing, as well as drug product formulation development, characterisation and product assay.
The Duncan Bryant Prize for the best poster, awarded by the Royal Society of Chemistry Molecular Spectroscopy Group, was won by Miss Rajni Miglani of Strathclyde University.
The Joint Pharmaceutical Analysis Group acknowledges with thanks the sponsorship of this symposium by the following companies: Clairet Scientific, Horiba, BaySpec, Lambda Photometrics and Cobalt Light.
DETAILS
Advances in Raman spectroscopy in pharmaceutical analysis
Royal Society of Chemistry, London
This major symposium was oganised jointly by the Federation of Analytical Chemistry and Spectroscopy Societies (FACSS), the Joint Pharmaceutical Analysis Group (JPAG), the Royal Society of Chemistry Molecular Spectroscopy Group (MSG) and the Infrared & Raman Discussion Group (IRDG)
Raman spectroscopy has found favour in pharmaceutical analysis because it is non-destructive, requires minimal sample preparation and gives clear spectra for identification. The programme demonstrated a breadth of successful Raman applications spanning the R&D field, active pharmaceutical ingredients (API) development, scale-up and manufacturing, as well as drug product formulation development, characterisation and product assay.
The Duncan Bryant Prize for the best poster, awarded by the Royal Society of Chemistry Molecular Spectroscopy Group, was won by Miss Rajni Miglani of Strathclyde University.
The Joint Pharmaceutical Analysis Group acknowledges with thanks the sponsorship of this symposium by the following companies: Clairet Scientific, Horiba, BaySpec, Lambda Photometrics and Cobalt Light.
DETAILS
Thursday 22nd March 2012
Advances in pharmaceutical analysis
Royal Society of Chemistry, London
Analytical technologies must evolve continuously to characterise increasingly complex pharmaceutical products and processes in an efficient and effective way.
This one-day symposium will examine developments in analytical techniques and practices to address current scientific and regulatory challenges in pharmaceutical development and quality control.
DETAILS
Advances in pharmaceutical analysis
Royal Society of Chemistry, London
Analytical technologies must evolve continuously to characterise increasingly complex pharmaceutical products and processes in an efficient and effective way.
This one-day symposium will examine developments in analytical techniques and practices to address current scientific and regulatory challenges in pharmaceutical development and quality control.
DETAILS
Thursday 22nd March 2012
JPAG Annual General Meeting
Royal Society of Chemistry, London
The 42nd Annual General Meeting of the Group will be held on Thursday 22nd March 2012 at the Royal Society of Chemistry, Burlington House, Piccadilly, London.
The AGM will commence at 9.30am, before the JPAG Conference ‘Advances in Pharmaceutical Analysis’
DETAILS
JPAG Annual General Meeting
Royal Society of Chemistry, London
The 42nd Annual General Meeting of the Group will be held on Thursday 22nd March 2012 at the Royal Society of Chemistry, Burlington House, Piccadilly, London.
The AGM will commence at 9.30am, before the JPAG Conference ‘Advances in Pharmaceutical Analysis’
DETAILS
Thursday 8th December 2011
Predictive tools in the development of solid oral dosage forms
Astronomical Society
Predictive modelling approaches are demonstrating increasing value throughout the product development cycle, from the prediction of physiochemical properties
of potential drug candidates in discovery, through the prediction of product characteristics and performance during clinical development, to the understanding of powder behaviour during large-scale manufacture.
DETAILS
Predictive tools in the development of solid oral dosage forms
Astronomical Society
Predictive modelling approaches are demonstrating increasing value throughout the product development cycle, from the prediction of physiochemical properties
of potential drug candidates in discovery, through the prediction of product characteristics and performance during clinical development, to the understanding of powder behaviour during large-scale manufacture.
DETAILS
Wednesday 31st August 2011
Measurement for the control of continuous processes
This seminar examined how innovative applications of measurement sciences are
pivotal to the implementation of the transition from batch to continuous processing, to deliver the full benefit of these changes as a key aspect of “The Science of Medicines”.
DETAILS
Measurement for the control of continuous processes
This seminar examined how innovative applications of measurement sciences are
pivotal to the implementation of the transition from batch to continuous processing, to deliver the full benefit of these changes as a key aspect of “The Science of Medicines”.
DETAILS
Thursday 7th July 2011
Best practice for outsourcing of analytical support and use of contract laboratories
Astronomical Society
Pharmaceutical and biotechnology companies now outsource at almost every stage of the product life cycle. This trend is supporting a thriving services sector by outsourcing a broad range of skills and technologies required for drug discovery, development and manufacturing. A substantial part of the outsourcing involves pharmaceutical analysis.
DETAILS
Best practice for outsourcing of analytical support and use of contract laboratories
Astronomical Society
Pharmaceutical and biotechnology companies now outsource at almost every stage of the product life cycle. This trend is supporting a thriving services sector by outsourcing a broad range of skills and technologies required for drug discovery, development and manufacturing. A substantial part of the outsourcing involves pharmaceutical analysis.
DETAILS
Thursday 16th June 2011
Analytical methods to combat the counterfeiting of medicines
Sub-standard and counterfeit medicines are a great threat to public health. They may cause death due to the absence of active drug, as found in some vaccines and antibiotics, or because of the presence of a toxic material, such as the substitution of diethylene glycol for glycerol.
Counterfeit medicines are estimated to constitute more than 10% of the global medicines market and in some developing countries it is thought to be as high as 50%. One prediction is that global counterfeit drug sales will reach $ 75 billion by 2011.
DETAILS
Analytical methods to combat the counterfeiting of medicines
Sub-standard and counterfeit medicines are a great threat to public health. They may cause death due to the absence of active drug, as found in some vaccines and antibiotics, or because of the presence of a toxic material, such as the substitution of diethylene glycol for glycerol.
Counterfeit medicines are estimated to constitute more than 10% of the global medicines market and in some developing countries it is thought to be as high as 50%. One prediction is that global counterfeit drug sales will reach $ 75 billion by 2011.
DETAILS
Thursday 24th March 2011
Counterfeit medicines: the regulatory and industrial challenges
Counterfeit medicines or -- more appropriately -- fake medicines are not a new phenomenon but continue to be a very dangerous threat to life and health. What is new, however, is the recent global escalation of counterfeit prescription medicines and healthcare products.
DETAILS
Counterfeit medicines: the regulatory and industrial challenges
Counterfeit medicines or -- more appropriately -- fake medicines are not a new phenomenon but continue to be a very dangerous threat to life and health. What is new, however, is the recent global escalation of counterfeit prescription medicines and healthcare products.
DETAILS
Tuesday 15th March 2011
Analytical challenges in the qualification and validation of pharmacodynamic biomarkers
Biomarkers are surrogates for the measurement of pharmacodynamic responses to drugs and vaccines.
At this symposium a panel of speakers presented current concepts in the qualification and validation of biomarker assays, including discussions on standard ELISA formats and the application of other platform technologies, including Flow Cytometry, ELISpot, Q-PCR, Gyros, LC/MS and multiplex platforms such as Luminex and Meso Scale Discovery (MSD).
The concept of a “fit-for-purpose” method qualification and validation, selection of reference material, QCs, and relevant acceptance criteria was examined. The various biomarker approaches including clinical diagnostics, immunogenicity, companion diagnostics and the use of commercial human kits for pre-clinical applications were reviewed.
Analytical challenges in the qualification and validation of pharmacodynamic biomarkers
Biomarkers are surrogates for the measurement of pharmacodynamic responses to drugs and vaccines.
At this symposium a panel of speakers presented current concepts in the qualification and validation of biomarker assays, including discussions on standard ELISA formats and the application of other platform technologies, including Flow Cytometry, ELISpot, Q-PCR, Gyros, LC/MS and multiplex platforms such as Luminex and Meso Scale Discovery (MSD).
The concept of a “fit-for-purpose” method qualification and validation, selection of reference material, QCs, and relevant acceptance criteria was examined. The various biomarker approaches including clinical diagnostics, immunogenicity, companion diagnostics and the use of commercial human kits for pre-clinical applications were reviewed.
Thursday 3rd February 2011
Measurement challenges in the analysis of topical products
The delivery of medicinal products to the skin or mucous membranes presents a number of challenges during product development and quality control of commercial products. This symposium addressed measurement challenges that arise with products for topical administration, focussing on analytical techniques used to characterise and control topical products, including creams, ointments, gels and products for inhalation.
The programme included contributions from key industrial, academic and regulatory speakers on fundamental techniques used to analyse topical products, such as rheology, thermal analysis, microscopy and gamma-scintigraphy.
Measurement challenges in the analysis of topical products
The delivery of medicinal products to the skin or mucous membranes presents a number of challenges during product development and quality control of commercial products. This symposium addressed measurement challenges that arise with products for topical administration, focussing on analytical techniques used to characterise and control topical products, including creams, ointments, gels and products for inhalation.
The programme included contributions from key industrial, academic and regulatory speakers on fundamental techniques used to analyse topical products, such as rheology, thermal analysis, microscopy and gamma-scintigraphy.
Thursday 2nd December 2010
Characterisation of active pharmaceutical ingredients
Royal Pharmaceutical Society of Great Britain
Characterisation of active pharmaceutical ingredients
Royal Pharmaceutical Society of Great Britain
Thursday 10th June 2010
Critical issues in the stability of products: focus on the industry-hospital interface
Royal Pharmaceutical Society of Great Britain
Critical issues in the stability of products: focus on the industry-hospital interface
Royal Pharmaceutical Society of Great Britain
Thursday 22nd April 2010
Chemometrics and multivariate statistics in pharmaceutical development
The Royal Pharmaceutical Society
Chemometrics and multivariate statistics in pharmaceutical development
The Royal Pharmaceutical Society
Thursday 4th March 2010
Quality by Design for analytical methods:a revolution in method lifecycle management?
The Royal Pharmaceutical Society
Quality by Design for analytical methods:a revolution in method lifecycle management?
The Royal Pharmaceutical Society
PAST EVENTS: 1970-2010
RETURN TO MEETINGS
WANT TO SEE MORE?
You will have access to materials for meetings that you have attended.
You will need to Sign In to activate access to your additional options.
Once Signed in, click on RESOURCES and look under MY PAST MEETINGS.
You will have access to materials for meetings that you have attended.
You will need to Sign In to activate access to your additional options.
Once Signed in, click on RESOURCES and look under MY PAST MEETINGS.
PAST MEETINGS
Symposium - October 2011
Delegates at a symposium held at the Royal Pharmaceutical Society
| Call us: | CONTACT US | Follow us: |     | Terms and Conditions Privacy Statement |
| Joint Pharmaceutical Analysis Group 2024 Website © and by Delta Consultancy Services |
|